6 Comments

CHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINES

CHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINES
Williams Hematology

CHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINES

PETER J. QUESENBERRY
GERALD A. COLVIN

Hematopoiesis

General Considerations

Stem Cells

Colony-Forming Unit Spleen
Specific Cytokines

Erythropoietin

Early-Acting Erythroid Cytokines

Colony-Stimulating Factors

The Other Interleukins

Thrombopoietin

Other Cytokines that affect Hematopoietic Stem Cells

Inhibitors of Hematopoiesis

Cytokine Receptors
Features of Stem Cells

Location of Lymphohematopoietic Stem Cells

Embryonic Origin of Lymphohematopoietic Stem Cells

Stem Cell Location and Modulation

Stem Cell Phenotype

Pluripotential Lymphohematopoietic (Marrow-Repopulating) Stem Cell
Adhesion Proteins and Receptors
Stem Cell Homing and the Microenvironment
Mobilization of Stem or Progenitor Cells
Chapter References

Acronyms and abbreviations that appear in this chapter include: AGM, aortogonadal mesonephros; BFU-E, burst-forming unit-erythroid; BRDU, bromodeoxyuridine; CFU-E, colony-forming unit-erythroid; CFU-GM, granulocyte-macrophage colony-forming unit; CFU-S, colony-forming unit spleen; CSF-1, colony-stimulating factor-1; FOG, friend of GATA-1; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; LIF, leukemia inhibitory factor; LTC-IC, long-term culture-initiating cell; MCAP, monocyte chemotactic and activating factor; M-CSF, macrophage colony-stimulating factor; MIP, macrophage inflammatory protein; MPLV, myeloproliferative leukemia virus; NK, natural killer; PDGF, platelet-derived growth factor; PTB, phosphotyrosine binding; SHZ, Src-homology; VLA, very late antigen.

HEMATOPOIESIS
GENERAL CONSIDERATIONS
The blood in mammalian species includes a number of different cell types essential for survival. Erythrocytes transport oxygen; platelets mediate blood clotting and support tissue integrity; neutrophil, eosinophil, and basophil granulocytes and monocytes are essential to host defense against bacteria, fungi, parasites, and viruses; T lymphocytes, natural killer cells, and dendritic cells all function as antigen-presenting cells and in cell-mediated immunity; and B lymphocytes are the source of antibodies. The level of these cell types is controlled by multiple humoral and cellular factors and adjusts rapidly to meet need. Infection by a variety of microorganisms results in almost immediate release of mature neutrophils from the marrow storage pool, followed by an increase in production of granulocytes, and usually also monocytes, until the infectious agents are cleared. Hemorrhage or acute hemolysis results in a rapid release of marrow reticulocytes, followed by a sustained increase in red cell production until the red cell numbers return to normal. Platelet production and release responds to several stimuli, including decreases in platelet number, acute anemia, and tissue destruction or inflammation. The modulation of T- and B-cell production is complex and occurs in response to immune stimuli (e.g., foreign antigens), and the modulation of increased production may occur within different subsets of these cells (see Chap. 83 and Chap. 84).
Mature cell types derive ultimately from marrow stem cells, which differentiate into progenitor cells that are controlled by circulating or membrane-bound cytokines or various adhesion proteins. A very small proportion of circulating cells are progenitor cells and stem cells, which can be isolated from the blood by special techniques.
STEM CELLS
A hematolymphopoietic stem cell is defined as a cell with extensive self-renewal and proliferative potential, coupled with the capacity to differentiate into the progenitors of all the blood cell lineages, that is, erythrocytes, neutrophil, eosinophil, and basophil granulocytes, mast cells, monocytes and macrophages, platelets, B lymphocytes, T lymphocytes, natural killer cells, and dendritic cells. Self-renewal refers to the potential to produce daughter cells with identical characteristics. Self-renewal resulting in production of identical stem cells without any new differentiated characteristics has not been established experimentally, but renewal on a cell population basis clearly occurs. The sequential development of progenitor cells and mature cells from stem cells is presented in Fig. 14-1.

FIGURE 14-1 Hierarchical model of lymphohematopoiesis.

Studies of both murine and human hematopoietic cells indicate that two daughter cells from a primitive undifferentiated cell can have totally different lineages, for example, one cell giving rise to neutrophils and monocytes, while the daughter cell may give rise to erythrocytes, megakaryocytes, and mast cells.1,2,3,4,5,6 and 7 These observations suggest a less-ordered or stochastic system in which the commitment decision to produce different lineages is made within one cell cycle transit, although concordance of daughter cells is still the rule, indicating a model in which there is ordered and progressive lineage restriction with differentiation. In general, as differentiated characteristics are attained, self-renewal potential declines precipitously.
The “gold standard” for the definition of a stem cell is the ability of that single cell to repopulate long-term hematopoiesis in the whole animal. The majority of stem cell studies have been carried out in mice, although one can infer the existence of long-term repopulating cells in humans based on the repopulation in patients given marrow ablative treatment and allogeneic marrow transplant. Studies in mice using unique radiation-induced chromosome abnormalities or retroviral markers have established the capacity of a very few cells (approaching one cell) to totally repopulate the lymphohematopoietic system.8,9,10 and 11 When relatively small numbers of marked stem cells, obtained by limiting dilution of sorted marrow cells, are transplanted, lymphohematopoiesis may be clonal or oligoclonal initially. Normal polyclonal lymphohematopoiesis derives from a relatively large number of clones. Studies of competitive marrow repopulation and mathematical modeling support the model of polyclonal hematopoiesis.12
COLONY-FORMING UNIT SPLEEN
Studies on the potential of single lymphohematopoietic cells to give rise to clones of progeny cells in vivo or in vitro provided the model systems for the detailed definition of lymphohematopoietic stem progenitor cells. The observation of “bumps” on the spleen after marrow infusion into lethally irradiated mice resulted in the first clonal hematopoietic stem cell assay.13,14,15,16,17,18,19,20,21,22,23,24,25,26 and 27 These splenic nodules were clones of hematopoietic cells containing erythroid, granulocytic, and megakaryocytic lineages, and the cells giving rise to the clones were termed colony-forming unit spleen (CFU-S). This assay is rarely carried out today, but characteristics of this cell illustrate the nature of stem/progenitor cells. This cell (the CFU-S) gave rise to variable, but large, numbers of differentiated cells, was influenced by the splenic microenvironment, was in a relatively quiescent (G0/G1) state, and reproduced itself. The CFU-S assay monitors cells with varying engraftment and growth potential but did not appear to be an assay for the most primitive long-term repopulating stem cell.
Perhaps the major breakthrough in the hematopoiesis field was the description of marrow cells with the capacity to form colonies of granulocytes and macrophages in vitro in the obligate presence of stimulatory factors present in conditioned media or serum (Fig. 14-2).28,29

FIGURE 14-2 Clonal assay for granulocyte-macrophage progenitor cells.

The characterization of the granulocyte-macrophage colony-forming cell (CFU-GM) and the molecules, which stimulated or inhibited its growth, was followed by the description of a number of different progenitors with different growth and lineage potential in in vitro clonal culture. These included clones with a single lineage such as granulocytic or erythroid or clones with multiple lineages including lymphocytes. In parallel with the description of these clonal entities, a growing number of cytokine regulators was described, purified, and then molecularly cloned. The different stem/progenitor clones are outlined in Table 14-1. General characteristics of lymphohematopoietic stem cells are presented in Table 14-2. Progenitor cells in general have a higher proliferative rate, i.e., are progressing through cell cycle, have less total proliferative potential, and show a restricted number of differentiated cell types. They are also responsive to a smaller number of cytokines; in essence they are defined by a limited number of cytokine receptors.

TABLE 14-1 HEMATOPOIETIC STEM/PROGENITOR CELLS ASSAYED IN VITRO

TABLE 14-2 PLURIPOTENTIAL HEMATOPOIETIC STEM AND PROGENITOR CELLS

The erythroid progenitors and their primary regulator, erythropoietin, were the first to be extensively studied. The presence of reticulocytes and iron incorporation to mark newly produced red blood cells and the capacity of induced polycythemia to shut off in vivo erythropoiesis provided an in vivo model for the study of erythroid regulation.30,31,32,33 and 34 A mouse was made polycythemic inhibiting its own erythropoiesis, a putative erythroid regulator was administered, and then red blood cell production was monitored by reticulocyte number or iron incorporation. These cumbersome in vivo models allowed for the initial definition of erythropoietin, but it took in vitro culture systems and the application of biochemical and molecular genetic techniques to provide biochemical characterization and molecular cloning of erythropoietin.
The studies with in vitro clonal culture system showed erythroid progenitors with different proliferative and differentiative potential.35,36 and 37 The more primitive erythroid progenitors termed burst-forming unit-erythroid (BFU-E) were defined by a high proliferative response to multiple cytokines, while the more differentiated colony-forming unit-erythroid (CFU-E) was responsive to erythropoietin and had limited proliferative potential (Fig. 14-3).

FIGURE 14-3 The erythroid differentiation pathway.

Erythropoietin was found to be active in vivo and in vitro30,31,35,36 and 37 and acted via a cell membrane receptor to induce erythroid differentiation38,39 and to suppress apoptosis or programmed cell death.40,41 It is one of the most specific of the lymphohematopoietic cytokines acting on erythroid cells, while many other cytokines show action on multiple lineages. The explicit actions of erythropoietin are described in Chap. 29, and its use in the treatment of anemia associated with a relative erythropoietin deficiency state (i.e., renal failure) is described in Chap. 33.
The CFU-GM, CFU-G, and CFU-M are progenitors in the granulocyte macrophage pathway regulated by a number of cytokines, but primarily granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), and macrophage CSF (M-CSF) or CSF-1 (Figure 14-4). These cytokines are active in vivo and G-CSF and GM-CSF are in use clinically for neutropenic states.

FIGURE 14-4 The granulocyte-monocyte-macrophage differentiation pathway.

The GM and G progenitors are also in cycle, have restricted lineages, and respond to a relatively small number of cytokines. As with erythropoietin, CSF-1 and to a lesser extent G-CSF are relatively lineage-specific, stimulating predominantly the production of monocyte-macrophages and granulocytes, respectively. These cytokines stimulate proliferation and differentiation and inhibit apoptosis through cell-surface–based receptors which send second messenger signals activating nuclear transcriptional mechanisms which then turn on or off various genetic programs.
There are a very large number of cytokines regulating hematopoiesis, certainly exceeding 60 to 70 in numbers. These cytokines and their most prominent hematopoietic activity are presented in Table 14-3, Table 14-4, and Table 14-5. There are an intimidating number of cytokines with a wide range of effects on lymphohematopoietic cells. These agents, however, have certain common features. The cytokines are glycoproteins acting at very low concentrations on receptor molecules to signal the cell to live, die, proliferate, differentiate, or function; many cytokines act on primitive stem cells and their functioning terminally differentiated progeny. These actions, particularly at the more primitive stem cell levels, may be on survival, proliferation, or differentiation or, alternatively, especially in mature cells, on function. Cytokines usually act on multiple lineages and multiple cell types and frequently act synergistically (or additively) to stimulate or inhibit. In many ways the progenitors are defined by their cytokine receptors.

TABLE 14-3 CYTOKINES ACTIVE ON LYMPHOHEMATOPOIESIS STEM AND PROGENITOR CELLS

TABLE 14-4 CYTOKINES ACTIVE ON LYMPHOHEMATOPOIETIC STEM OR PROGENITOR CELLS (GROWTH FACTORS)

TABLE 14-5 CYTOKINES ACTIVE ON LYMPHOHEMATOPOIETIC STEM CELLS: CYTOKINE INHIBITORY FACTORS AND OTHERS

SPECIFIC CYTOKINES
The broad-based actions of cytokines on hematopoietic cells are complex and evolving. Most cytokines have many actions on different lineages and stages of differentiation. Descriptions of the biologic, biochemical, and molecular genetic characteristics of these cytokines follows.
ERYTHROPOIETIN
Erythropoietin was first defined in in vivo assays. The initial definition was provided in the 1950s.30,31 The hormone was later purified, its sequence determined, and the gene encoding its production cloned.117,118 and 119 The clonal culture systems for BFU-E, CFU-E, and intermediate erythroid progenitor cells facilitated investigation of the biology of erythropoietin (Fig. 14-3). Erythropoietin is produced in the renal peritubular interstitial cells121,122 or renal tubular cells.123 There are also measurable erythropoietin levels in anephric animals and humans presumably of hepatic origin.124,125,126 and 127 Hepatocytes and Kupffer cells have been implicated as the cell of origin for hepatic erythropoietin.128 Marrow macrophages may also be a source of erythropoietin.129 The tissue oxygen-sensing mechanisms that are linked to erythropoietin elaboration may involve a heme protein.130 Further details of the structure, function, and regulation of erythropoietin are presented in Chap. 29.
The response of BFU-E and CFU-E to erythropoietin correlates directly with the presence of erythropoietin receptors. Two classes of erythropoietin receptor, high and low affinity, have been identified on erythroblasts obtained from the spleens of mice infected with the anemia strain of Friend virus.39 The receptor has been cloned38 and belongs to the hemopoietic family of receptor proteins. The cell cycle behavior of BFU-E131 in vivo is not influenced by hypoxia (increased erythropoietin) or hypertransfusion (decreased erythropoiesis), and BFU-E can proliferate in vitro in the absence of exogenous erythropoietin when in the presence of other cytokines.132 Actinomycin given to mice blocks the action of erythropoietin on CFU-E and more mature erythroid cells, virtually eliminating them in vivo, but has no effect on the numbers of marrow and splenic BFU-E.133 Monoclonal antibody purified blood BFU-E do not require erythropoietin until after 72 h of culture. Initially only 20 percent of BFU-E have erythropoietin receptors, but with maturation in vitro over 4 days 100 percent of the cells bind 125I erythropoietin. The peak receptor number occurs at the CFU-E stage, the main target cell for the action of erythropoietin. CFU-E does not have the proliferative potential of BFU-E but requires erythropoietin for limited proliferation, survival, and terminal maturation.88 CFU-E is responsive to low concentrations of erythropoietin.89 Adding erythropoietin to CFU-E in vitro leads to rapid expression of mRNA for alpha and beta globins, and hemoglobin synthesis commences soon thereafter.134 Erythropoietin also stimulates the proliferation of proerythroblasts and basophilic erythroblasts,135 but with maturation beyond the basophilic erythroblast stage, the erythroid cells no longer appear to require erythropoietin for maturation or function136; many erythroid cells, including late-stage erythroid progenitors, undergo programmed cell death or apoptosis, and this is prevented by erythropoietin. The action of erythropoietin on second messenger and transcriptional factors is outlined below.
EARLY-ACTING ERYTHROID CYTOKINES
A critical observation was that erythropoietin does not act on BFU-E or other early progenitors alone, but rather in concert with other cytokines. These include IL-3,137,138 GM-CSF,139 IL-9,140 steel factor,137 interleukin 4,141 and insulin-like growth factor.1 This list will grow with increased purity of the progenitors or omissions of serum from the cultures.
There are strong similarities between erythropoietin growth control and the action of other lymphohematopoietic cytokines. These include (1) an action on proliferation and maturation; (2) an effect on cell survival inhibiting apoptosis; (3) an action mediated through cell surface receptors; and (4) synergistic interactions with a number of other cytokines.
COLONY-STIMULATING FACTORS
These were first defined by the stimulation of granulocyte-macrophage colonies in soft agar culture. The four colony-stimulating factors are CSF-1 or M-CSF, GM-CSF, G-CSF, and IL-3 (multi-CSF).
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
GM-CSF was first defined by its ability to stimulate colonies of neutrophils and macrophages in soft-agar culture, but it acts on many cell types, including relatively early multipotential stem cells, megakaryocyte, eosinophil erythroid, dendritic progenitors, and mature neutrophils and macrophages.83,84,85,86 and 87 GM-CSF was first isolated from murine lungs142 and later from a human T-cell leukemia line.143 Human GM-CSF is a glycoprotein with a Mr of 22,000, and murine GM-CSF is a glycoprotein with a Mr of 23,000.
The murine gene was cloned from a murine lung cDNA library144 while the human cDNA was isolated from a human leukemia cell line.145,146 The human GM-CSF contains 127 amino acids with an Mr of 14,000, and the human gene was isolated on chromosome 5 147,148 with a control region 5 prime of the gene.149 GM-CSF stimulates proliferation and maturation of bipotential neutrophil and macrophage progenitors and has multiple actions on mature cells including stimulation of synthesis of membrane and nucleoproteins in murine granulocytes,87 increased adhesion protein expression in neutrophils,150 inhibition of neutrophil migration,143 and stimulation of cytotoxic and phagocyte activity against bacteria, yeast, parasites, and antibody-coated tumor cells,151,152,153 and 154 enhanced survival and cytotoxicity of human neutrophils and eosinophils in vitro,155 and increased basophil histamine release. GM-CSF also increases neutrophil superoxide production in response to bacterial chemoattractants and increases neutrophil arachidonic acid release and leukotriene B4 synthesis in response to calcium ionophore and chemoattractants.156,157 GM-CSF also induces changes in neutrophil calcium flux and pH after treatment with a chemotactic agent.
GM-CSF mediates its effects by binding to a specific cell receptor (see below).158,160 GM-CSF controls the proliferation of GM-CSF–dependent cells during the GI phase of cell cycle.161
The availability of recombinant growth factor has permitted studies of bioactivity of GM-CSF in vivo. Administration of GM-CSF to murine species and to primates causes increases in granulocytes, monocytes, eosinophils, and, to a lesser extent, other white cell types in both normal animals or animals subjected to cytotoxic or irradiation-induced marrow suppression.162,163,164,165,166,167 and 168 GM-CSF may also raise the platelet count and possibly the reticulocyte level,162,164,166 although in some patients the platelet count is lowered.
Administration of GM-CSF to humans with AIDS results in a dose-dependent increase in neutrophils, eosinophils, and monocytes.169 The administration of GM-CSF during chemotherapy lessens the fall in the neutrophil count.170,171 GM-CSF stimulates proliferation of about one-third of human cancer cell lines, including small-cell lung carcinoma, ovary, breast, colon, and melanoma. Other effects of GM-CSF include lowering of serum cholesterol, mobilization of blood progenitors, induction of inflammatory recall, and a capillary leak syndrome. GM-CSF is licensed for therapeutic use.
GRANULOCYTE COLONY-STIMULATING FACTOR
G-CSF was first defined as a factor that had the capacity both to stimulate normal granulocyte colonies and to induce maturation of leukemic cell lines.81,82 It has been purified to homogeneity from mouse lung (Mr = 25,000).172 Human G-CSF has a similar molecular size and cross-reacts with both human and murine cells. cDNAs for both murine and human G-CSFs have been cloned.172,173 The human cDNA encodes a polypeptide with a 30 amino acid signal sequence followed by mature G-CSF sequence of 177 amino acids. The molecular mass is 19 KD. These proteins stimulate predominantly neutrophil colony formation. The gene for human G-CSF has been localized on chromosome 17.174 G-CSF can initiate the proliferation of some granulocyte-macrophage progenitors but does not sustain this beyond several days. G-CSF interacts with a number of cytokines to stimulate blast colony and high proliferative potential colony-forming cell development in vitro, induces terminal maturation in WEHI-3B myelomonocytic leukemic cells,85 and stimulates pre-B cells in vitro.175 G-CSF also affects mature progeny; priming human neutrophils to undergo oxidative metabolism in response to formyl-methionlleucylphenylanine, as well as increasing antibody-dependent cell-mediated cytotoxicity of human neutrophils. G-CSF primes human neutrophils for enhanced arachidonic acid release, and receptors for G-CSF have been identified on both human neutrophils and leukemic cell lines.176 G-CSF also stimulates proliferation and variable degrees of maturation in acute myelogenous leukemia blast cells177,178 and stimulates proliferation of a variety of human solid tumor cell lines. G-CSF is active in vivo in mice, hamsters, primates, and humans, stimulating impressive neutrophil increases with lesser increases of monocytes, lymphocytes, and possibly platelets.179,180,181,182,183,184,185,186,187 and 188
G-CSF has been licensed for therapeutic use.
COLONY-STIMULATING FACTOR 1 (MACROPHAGE COLONY-STIMULATING FACTOR)
CSF-1 (M-CSF) stimulates a population of progenitor cells with a high predilection for macrophage maturation, although early in the culture period there may be some granulocyte production. CSF-1 binds rapidly to mature macrophages and is internalized and degraded. Low levels of CSF-1 support survival of murine marrow macrophages while decreasing their level of protein catabolism. Higher levels of CSF-1 stimulate protein synthesis, cell division,189,190 and various macrophage functions, including antitumor activity,191 secretion of products of oxygen reduction,192 and plasminogen activator.193,194 and 195 CSF-1 also induces production of IL-1 from macrophages.196 The product of the FMS gene is the receptor for CSF-1.197,198 and 199 The receptor is a tyrosine kinase, which autophosphorylates. The number of monocyte receptors increases with maturation and may be induced by other growth factors, including IL-3 and IL-1, explaining the synergistic effects of the combinations either of CSF-1 or IL-3 and IL-1 on in vitro macrophage colony formation.79,200,201 CSF-1 induces macrophage cell lines to progress through cell cycle by modulating levels of specific cyclins.202 CSF-1 can increase neutrophil levels and lower cholesterol in vivo.
CSF-1 has been purified to homogeneity79,80,203,204 and 205 from both murine and human sources. Human urinary CSF-1 is a heavily glycosylated homodimer of 45 kD,206 whereas the material purified from L-cell-conditioned medium is a glycoprotein of 70 kD.79,80,203 Its basic structure is that of a homodimeric protein of 28 kD consisting of two 14-kD peptide chains. Varying degrees of glycosylation explain, in part, different estimates of molecular size. Genes for both human and murine CSF-1 have been cloned and expressed in vitro.207,208 The human CSF-1 gene is a single gene encoding several differentially spliced mRNA transcripts ranging from 1.5 to 4.5 kb. Several different sizes of human CSF-1 have also been purified from natural sources; the smaller variety possibly being a proteolytic degradation product of a larger 70- to 90-kD glycoprotein. Higher-molecular-weight forms bound to proteoglycans have been reported.209
INTERLEUKIN-3 (MULTI-COLONY-STIMULATING FACTOR)
A fourth murine T-cell-derived regulator, interleukin-3 (IL-3) or multi-CSF, has been characterized,49 purified,210,211,212,213 and 214 and genetically cloned.215,216,217,218 and 219 It stimulates growth of granulocytes and monocytes, but also has megakaryocyte, erythroid, mast cell, and possibly T-cell growth stimulatory activity. Il-3 was cloned from a gibbon T-cell line.50 Il-3 was initially believed to be T-cell specific49,220 but has now been established as a major multilineage stimulator with direct megakaryocyte-, mast cell–, basophil-, B-cell-, and eosinophil-stimulating ability. It also interacts with erythropoietin to stimulate primitive erythroid stem cells,221 with CSF-1, GM-CSF, and IL-1a to stimulate the growth of high proliferative potential colony-forming cells222 and supports the formation of early multilineage blast cells in vitro.223 It is identical to the “stem cell activating factor” that induced CFU-S to proliferate. Recombinant IL-3 is an activating factor for basophils, mast cells, and eosinophils but not neutrophils. In vivo administration to mice induces 10-fold increases in blood eosinophils and 3-fold increases in granulocytes and monocytes. Splenic hematopoiesis is increased with prominent effects on mast cells, and many tissues show an increase in macrophages or mast cells.47 Single injections of IL-3 induce most types of murine marrow progenitors into cell cycle. In murine species, IL-3, GM-CSF, and CSF-1 in low doses, act synergistically to induce progenitor cell cycling,48,224 and sequential treatment of primates with recombinant human IL-3 followed by low-dose recombinant human GM-CSF synergistically increases blood neutrophil, monocyte, lymphocyte, and eosinophil levels. IL-3 alone augments reticulocyte and platelet levels in nonhuman primates.225 Administration of IL-3 to normal or myelosuppressed humans stimulates increases in a similar range of cell types, but its ability to raise platelet levels has been marginal.226,227 This, along with a relatively high incidence of toxic side effects, has lessened the enthusiasm for the use of IL-3 as a single agent in therapy.
THE OTHER INTERLEUKINS
Cytokines with pleiotropic actions are referred to as interleukins. Their principal actions on lymphohematopoiesis are presented in Table 14-3.
INTERLEUKIN-1
IL-1, identical with the previously described endogenous pyrogen- and lymphocyte-activating factor, was initially defined as a macrophage product that induces IL-2 receptor expression on T lymphocytes.42,43 It is produced by many different cell types in response to inflammatory stimuli and has two molecular forms, IL-1-a and IL-1-b, which have a low level of homology but similar activities and share a common receptor. The activity of IL-1 is further modulated by the IL-1 receptor antagonist.228 IL-1 shares many properties with IL-6 (and probably also IL-11) and is involved in the regulation of the immune system, induction of fever, acute phase protein production, tissue repair, and cytotoxicity.42,43,229 IL-1 has apparent direct effects on early hemopoietic stem cells and acts synergistically with many other factors to augment proliferation of high proliferative potential colony-forming cells, CFU-blast, and myelogenous leukemia blasts.230,231,232,233 and 234 IL-1 is also an inducer of other growth factors such as G-CSF, GM-CSF, and IL-3 from different cell types including fibroblasts, endothelial cells, monocytes, keratinocytes, and thymic nonlymphoid cells.235,236,237,238,239 and 240 Studies in vivo in mice and humans indicate that IL-1 augments hemopoietic recovery probably by an action on early stem cells.241,242 In addition, it interacts synergistically in vivo with other cytokines to accomplish the same end. Its use as a sole agent clinically may be limited by toxic manifestations including hypotension, hypoglycemia, fever, rigors, and headache.
INTERLEUKIN-2
IL-2 is T-cell growth factor44 (see Chap. 84). It augments production of other lymphokines such as gamma interferon and is produced by T cells and stimulates and activates B cells and natural killer cells, modulating the expression of histocompatibility antigens.243 IL-2 may inhibit both granulocyte-macrophage colony formation and erythropoiesis.45,46 The immune modulatory functions of IL-2 have been applied to the treatment of cancers. IL-2 alone, or in combination with other cytokines and cell populations, has some effects against melanoma and renal cell carcinoma.
INTERLEUKIN-4
IL-4, also known as B-cell stimulating factor 1, B-cell differentiation factor, and IgG induction factor,51,52,244,245 stimulates B-cell maturation, immunoglobulin synthesis, and generation of cytotoxic and helper T lymphocytes (see Chap. 83 and Chap. 84). It interacts with a variety of other growth factors to stimulate granulocyte-macrophage, mast cell, erythroid, and megakaryocyte proliferation in murine systems.246,247 It also interacts with IL-11 to stimulate the proliferation of dormant hemopoietic progenitors cells247 and conversely may exert inhibitory influences on IL-3–dependent erythroid colony formation.248 It also stimulates proliferation and differentiation of dendritic cells.
INTERLEUKIN-5
IL-5, also known as T-cell replacing factor,249 B-cell growth factor-2,250 and eosinophil differentiation factor,53 supports the proliferation, maturation, and function of eosinophils (see Chap. 68). IL-5 also can stimulate both proliferation and differentiation of different leukemic blasts from different subsets of patients with acute myelocytic leukemia. IL-5 has a variety of effects on promoting maturation of proliferation of B cells and like CSF-1 is a homodimer.
INTERLEUKIN-6
IL-6, also previously called interferon B-2, hybridoma growth factor, B-cell stimulating factor 2, B-cell differentiation factor, and hybridoma plasmacytoma growth factor, is produced by a variety of different cell types and was originally cloned from a T-lymphocyte cDNA library as a molecule inducing immunoglobulin production by B lymphocytes.56,57,251,252 and 253 IL-6 also has direct proliferative effects on hemopoietic cells and interacts synergistically with other growth factors to stimulate myeloid proliferation.57,254,255 and 256 It is a potent mitogen for B cells and also induces T-cell growth and maturation. It has activity on hematopoietic blast colony-forming cells and is a major factor in the immune response and inflammation. IL-6 augments colony formation induced by other growth factors and stimulates granulocyte-macrophage and megakaryocyte colony formation. IL-6 also has in vivo activity stimulating platelet production in normal and myelosuppressed mice, primates, and humans.257,258 and 259 Neutrophil elevations are also seen. IL-6 stimulates blasts from patient with acute myelocytic leukemia260 and has been implicated as an autocrine or paracrine factor in multiple myeloma (see Chap. 106).261 Other diseases in which IL-6 may play a role, and be responsible for the systemic manifestations, include atrial myxoma, Castleman’s disease, and rheumatoid arthritis.262
INTERLEUKIN-7
IL-7, also known as lymphopoietin-1, is a B-cell activating factor that appears to have effects on T-cell stimulation and on immature blood granulocyte and splenic megakaryocyte regeneration in irradiated mice.58,59,263 IL-7 shows potent interactions with KIT ligand in inducing pre-B cells in culture264 (see Chap. 94).
INTERLEUKIN-8
IL-8 is a chemotactic factor for granulocytes that has been termed neutrophil-activating peptide.60,61 and 62 It induces immediate inflammatory responses on intracutaneous injection and a granulocytosis after intravenous injection, apparently by redistributing blood and/or splenic granulocytes.63,64 It is part of the family of proinflammatory molecules linked by amino acid homology, chromosome location of their genes, and a position-invariant cysteine motif.64 These include, under the chemokine b classification, Gro-a, macrophage inflammatory protein-2-b (MIP-2-b), platelet factor 4 (PF4), IL-8, neutrophil activating protein-2 (NAP-2) and interferon-inducible protein-10 (IP-10).64,265,266 and 267 The following all inhibit in progenitor assays: MIP-1a, MIP-2a, PF4, IL-8, IP-10, and monocyte chemotactic and activating factor (MCAF); they also show synergistic inhibition when tested in combination.267 These molecules tend to inhibit more primitive progenitors and may stimulate growth of more mature progenitors. They are potent mobilizers of stem and progenitor cells.
INTERLEUKIN-9
IL-9, or mouse T-cell growth factor, P40, supports the development of erythroid bursts (BFU-E) in cultures supplemented with erythropoietin.268,269 Recombinant murine and human IL-9 were cloned from T-cell lines, and the sequence of recombinant human IL-9 bears homology with mouse T-cell growth factor, P40.269,270 IL-9 also has mast cell growth-promoting activity and stimulates maturation of multilineage and myeloid colony-forming cells from fetal cells.65,271
INTERLEUKIN-10
IL-10 was initially characterized as cytokine synthesis inhibitory factor and is able to inhibit interferon-g production by activated T-cell clones.272 IL-10 also appears to have direct effects on mature T cells, increasing the frequency of cytotoxic T-cell precursors and increasing cytotoxic effect or function.273 It also synergistically stimulates mast cell growth and induces MHC class II antigen expression on and increased viability of B cells.66,274
INTERLEUKIN-11
IL-11 has many of the biologic effects produced by IL-6.67,68 and 69,275,276 and 277 IL-11 stimulates B-cell, megakaryocyte, and mast cell lineages, along with early multipotential progenitor cells (e.g., CFU-blast).68,69,275,276 and 277 IL-11 stimulates platelet production in mice and primates278,279 but also stimulates increased neutrophil levels.
INTERLEUKIN-12
IL-12 is a natural killer cell stimulatory factor or cytotoxic lymphocyte maturation factor.70,280,281,282,283 and 284 IL-12, in synergy with IL-2, increases generation of cytotoxic T cells and of lymphokine-activated killer cells, increases cytotoxic activity of natural killer cells, promotes proliferation of activated T cells and natural killer cells, and induces interferon-g production by resting or activated natural killer cells and T cells.
INTERLEUKIN-13
IL-13, a T-cell–derived cytokine, was cloned and shown to share many biologic activities with IL-4.71,285 Both IL-4 and IL-13 inhibit cytokine production by blood monocytes, affect the proliferation and maturation of B cells to antibody-producing cells,285 and cause a switch to IgG4- and IgE-producing cells by naive human B cells. IL-13, in contrast to IL-4, induces the production of interferon-g by large granular lymphocytes and, in contrast to IL-4, has growth stimulatory effects on activated T cells.
INTERLEUKIN-14
IL-14, also known as high-molecular-weight B-cell growth factor, induces B-cell proliferation, inhibits immunoglobulin synthesis/secretion, and acts as a B-cell growth stimulant for certain subpopulations.286,287 IL-14 is produced by T cells and some B-cell malignancies such as B-cell precursor acute lymphocytic leukemia, chronic lymphocytic leukemia, and B-cell lymphoma.287,288 and 289 Exogenous IL-14 has been shown to have putative proliferative activity on B-lymphoma cells in vitro when other B-cell stimulatory cytokines such as IL-2, IL-4, IL-6, or tumor necrosis factor do not have increased activity, suggesting a paracrine effect. IL-14 also has been shown to have an autocrine growth factor effect for intermediate to high-grade B-lymphoma cells. In fact, in vitro studies suggest that many of the B-cell malignancies could be immunomodulated to inhibit proliferation by an antisense oligonucleotide to IL-14.288
INTERLEUKIN-15
IL-15 shares biologic activity with IL-2 as well as components of the IL-2 receptor. IL-15 is a cytokine, having multiple levels of receptor and signaling pathways and expression control. Expression occurs at many tissue beds throughout the body, stimulating the proliferation of activated CD4+, CD8+, gd subset of T cells, natural killer (NK) cells, and mast cells. Il-15 acts as a potent T-cell chemoattractant and acts as a costimulator with IL-12 to facilitate production of IFNg and TNFa. IL-15 may act as an anabolic agent that increases muscle mass and help with the differentiation and maturation of the immune system. Unlike IL-2, IL-15 is not expressed by T cells, but it does stimulate mast cells and is believed to be responsible for inducing the pathological propagation of mast cells that leads to mastocytosis.290,291,292,293 and 294
INTERLEUKIN-16
IL-16 is an immunomodulatory and proinflammatory cytokine that acts as a CD4+ T-lymphocyte chemoattractant and growth factor stimulant.295,296 IL-16 is synthesized as an 80-kDa peptide precursor molecule that gets processed to a biologically active 14- to 17-kDa protein. Functional bioactivity is dependent on autoaggregation of the pepide to homotetramers (56 kDa).296 The gene is located on chromosome 15 (q26.1).297 The gene location and IL-16 structure are unique, without significant homology to other interleukins or chemokines. IL-16 synthesis is produced by stimulated CD4 and CD8 T cells, eosinophils, mast cells, and epithelial lung cells stimulated by chronic inflammation of asthma.295,296 and 297 Prominent immunomodulatory effects are seen with this cytokine with repression of HIV/SIV transcription and replication.295,296,297 and 298 IL-16 activity has been associated with granulomatous disease states (sarcoidosis, tuberculosis), asthmatic inflammation,299 primary IgA nephropathy,300 rheumatoid synovitis (possible anti-inflammatory effects),301 systemic lupus erythematosus,320 and allergic contact dermatitis.303
INTERLEUKIN-17
IL-17, also referred to as cytotoxic T-lymphocyte–associated antigen 8 or murine CTLA-8 is a 155 amino acid glycoprotein homodimer, which stimulates adherent cells such as macrophage, epithelial, endothelial, keratinocyte, or fibroblast to secrete a variety of cytokines including IL-6, IL-8, G-CSF, LIF, TNF-alpha, IL-1 beta, IL-10, IL-12, and IL-1R antagonist. It induces ICAM-1 surface expression, proliferation of T cells, growth and differentiation of CD34+ human progenitors into neutrophils when cocultured with irradiated fibroblasts, and osteoclast progenitor differentiation to osteoclasts.304,305,306,307,308,309,310,311,312,313,314,315,316 and 317 It also inhibits IFN-gamma- and TNF-alpha-induced production of Rantes. It stimulates granulopoiesis in vivo, and it is produced by CD4+ and CD8+ T cells and alpha-beta TCR + CD4 – CD8-T cells.308,318,319
INTERLEUKIN-18
Interleukin-18 is also known as interferon-g–inducing factor or interleukin-1 g. Functional properties are similar to IL-12. Produced by a wide variety of cells, it augments cell-mediated immunity, modulates T, B, and NK function, induces interferon gamma in type 1 helper T and NK cells, initiating immune and antitumor effects, augmenting GM-CSF, and decreasing IL-10 production. Pretreatment or early treatment with IL-18 in mice confers resistance or protection in many types of tumors.320,321,322,323,324,325,326,327,328,329,330,331,332,333 and 334
KIT LIGAND (STEEL FACTOR)
The SI/SId and W/Wv mice exhibit macrocytic anemia, pigmentation, and germ cell defects.335,336,337,338,339,340,341,342 and 343 These mice have a macrocytic anemia and other more subtle defects in multilineage hematopoiesis. They also have germ cell (sterility) and melanocyte (coat color) defects. The W/Wv mouse has a CFU-S stem cell deficiency, whereas the S1/S1d mouse has a stromal cell (microenvironmental) defect, since stromal (irradiated spleen) cells from W/Wv will cure the anemia of S1/S1d mice, while marrow stem cells from S1/S1d will cure the anemia of W/Wv mice. The defect in W/Wv mice was found to be due to abnormalities in the tyrosine kinase KIT receptor,344,345,346,347,348,349,350 and 351 while subsequently the defect in S1/S1d has found to be due to a deficiency of the ligand for the KIT receptor.352,353,354 and 355 This protein exists in both membrane and soluble forms and may serve both to bind and stimulate stem cells. This protein KIT ligand is the same as hemolymphopoietic growth factor-1175 and synergizes with a large number of cytokines to stimulate early high proliferative potential colony form cells, possibly acting as a survival factor. It exerts action on all myeloid pathways and in the presence of IL-7 stimulates pre-B cell generation in vitro. It also stimulates the functional activation of mast cells. KIT-ligand has multilineage effects in mice, primates, and humans, but its mast cell activation and associated allergic toxicities may limit its clinical use, at least as a single agent.
THROMBOPOIETIN
A number of investigators strived to define the humoral regulator of megakaryocytopoiesis and platelet production.356,357 and 358 Critical insights were generated studying the transforming oncogene (v-mpl) of MPLV, an acute transforming murine retrovirus,359,360 which induces a pan-myeloid disorder.361 Thrombopoietin was cloned in 1994362,363,364 and 365 and was found to be the ligand for c-Mpl, the normal cellular receptor and counterpart to v-Mpl. Thrombopoietin appears to be the major regulator of megakaryocyte proliferation, differentiation, and platelet production. It also induces platelet-specific proteins and ultrastructural features and increased endomitosis.366 It also has action on multiple other hematopoietic lineages and is a major regulator of primitive multilineage stem cells. Administration of thrombopoietin to normal or myelosuppressed mice increased progenitor cells of all hematopoietic lineages and hastened hematopoietic recovery.367,368 Other studies have indicated that thrombopoietin exerts potent effects on early multipotent hematopoietic stem cells inducing entry into cell cycle369 maintaining or expanding LTC-IC in vitro.370 Furthermore, hematopoietic repopulating cells appear to be localized to the mpl + population371 and disruption of the mpl gene reduces murine stem cells as assayed in a competitive repopulation assay.372
OTHER CYTOKINES THAT AFFECT HEMATOPOIETIC STEM CELLS
There are a daunting number of other regulators that impact on the lymphohemopoietic pathways either as stimulators or inhibitors, some showing both effects dependent on the stage of maturation of the lineage under consideration. Leukemia inhibitory factor (LIF), which supports proliferation of the IL-3-dependent cell line DA-1,108 also sustains the proliferation of embryonic stem cells, inhibits adipogenesis, induces renal cell differentiation, neuronal development and differentiation, and bone remodeling. It stimulates proliferation of megakaryocyte progenitors and possibly CFU-S.109
Basic fibroblast growth factor also is a pleiotropic growth factor that stimulates primitive marrow stem cells, megakaryocyte progenitors, and marrow stromal cells.113,114 and 115 Insulin-like growth factors I and II stimulate erythroid and myeloid progenitors,110,111 and hepatocyte growth factor synergizes with other factors at the progenitor’s cell level.112 Platelet-derived growth factor acts on erythroid and granulopoietic progenitors and indirectly on early multilineage stem cells.116
Flt-3 ligand acts on relatively primitive progenitor stem cells showing synergies with G-CSF, GM-CSF, M-CSF, IL-3, and SCF and stimulates dendritic cell formation90,91,92 and 93; Flt-3 ligand can also induce tumor regression in vivo.94
INHIBITORS OF HEMATOPOIESIS
Inhibitors of hematopoiesis have been difficult to study due to questions of the specificity and physiologic relevance of their effects. However, with the progressive definition of cytokines, coupled with advances in cell purification and the use of serum-free culture systems, a number of molecules have been established as having specific inhibitory effects on different stem or progenitor cells. Some of these molecules may exert inhibitory effects on early, more primitive stem cells, while stimulating their latter, more differentiated progeny. A number of inhibitors with varying action are presented in Table 14-5.
Transforming growth factor beta has received the most attention for its ability to inhibit early stem cells, while stimulating more mature cells,103,104 possibly through modulating surface cytokine receptor expression.373
The chemokine family of inhibitors and the small peptides are presented in Table 14-5. The chemokine family was outlined in the description of IL-8. The beta subfamily contains a position invariant cysteine-x-cysteine motif, and its genes are on human chromosome 17, while the alpha subfamily contains position invariant cysteine-x-cysteine motif, and its genes are on human chromosome 4. These inhibitor molecules are potential marrow cell protectors, since they can block entry of stem cell into S phase of the cell cycle (tetrapeptide),107 remove cells from S phase (pentapeptide),106 or do both (MIP-1a and related family members) in a rapid and reversible manner.
CYTOKINE RECEPTORS
Cytokines influence cell behavior by binding to cell-surface-receptor proteins and then sending messages for various cell responses. There are a number of receptor families that have been described.
The hematopoietic receptor family includes IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, G-CSF, GM-CSF, and erythropoietin.374,375,376 and 377 The extracellular binding domains of these receptors contain four conserved cysteine residues and a WS-X-WS motif (X is a variable nonconserved amino acid). Some also have immunoglobulin-like structures. GM-CSF, IL-3, and IL-5 receptors contain specific low-affinity alpha chains and a high-affinity beta chain shared by each receptor.377 The common beta chain plays a role in the competitive binding of these ligands.
The tyrosine kinase receptor family includes receptors for FLT-3 ligand, c-KIT, PDGF, CSF-1, and thrombopoietin.90,197,198 and 199,349,350 and 351 These receptors have an immunoglobulin-like structure and conserved cysteines in the extracellular domain with tyrosine kinase activity in the cytoplasmic domain.
Typical steps for the action of a cytokine on a hematopoietic cell (or any other cell) include receptor oligomerization with activation of tyrosine kinase activity, phosphorylation of the receptor, and recruitment of Src-homology (SHZ) and phosphotyrosine binding (PTB) domain proteins to the receptor. What follows varies between different cytokines but in essence represents a series of enzymatic phosphorylation-dephosphorylation steps with final evolution of a protein or protein complex that binds to DNA to initiate genetic programs. Signaling through the GM-CSF, IL-3, and IL-5 receptors, which share a common beta chain, illustrates some specifics of these complex and evolving second messenger systems. The beta chain without kinase activity induces tyrosine phosphorylation of itself along with an increasing number of cytoplasmic proteins including kinases such as PI-3 kinase,378 adapters illustrated by Grb2,379 the insulin receptor substrate-2,380 Cbl,381,382 and SHC383,384; guainine nucleotide exchange factors such as Vav382,383,385; phosphatases such as SH-2–domain protein tyrosine phosphatase-2378,379,383,386 and SH2 containing inositol phosphatase387 and transcription factors such as STAT 5.386,387 and 388 Receptor phosphorylation is mediated by receptor-associated kinases such as JAK2389 and Src-family kinases.390 These sequential interactions lead to proteins, usually in complexes that bind to regions of DNA and in turn prompt initiation of transcription, guiding different genetic programs which modify or effect cell death, proliferation, differentiation, or function.391
These transcription factors have been characterized in adult mammals and perhaps most extensively in a variety of developmental studies utilizing mouse, xenopus, drosophila, c. elegans, and zebra fish and employing transgenic techniques for knock-outs, knock-ins, and overexpression. This is also an evolving field, but certain transcription factors appear to be responsible for certain differentiation pathways. Factors acting at the earliest stem cell levels include C-myb, p45-NF-E2, GATA-2, AML-1, and tal-1/SCL, while IKaros and PU-1 may act at the earliest lymphoid level. In the myeloid pathways, PU-1 appears to influence granulocyte and monocyte differentiation; PAX-5 B-lymphoid development; GATA-1 erythroid, mast cell, and megakaryocyte lineages; and P45-NF-EC the megakaryocyte lineage. FOG (friend of GATA-1) acts in concert with GATA-1.392
These transcription factors appear to act in complexes, binding to DNA regions. An example is the recently described complex of SCL, LMO-2, GATA-1, E47, and Lbdl/NLI.393 Further definition of these systems promises to define the genetic bases for lymphohematopoietic regulation.
FEATURES OF STEM CELLS
LOCATION OF LYMPHOHEMATOPOIETIC STEM CELLS
Current theories of hematopoietic stem cell sites of origin and the hematopoietic potential of marrow cells have been reexamined as a result of unexpected findings. Convincing evidence has been found that cloned neural (brain) stem cells can repopulate an irradiated host giving rise to multilineage hematopoiesis.394 Further studies have indicated that isolated muscle satellite cells can also give rise to hematopoiesis.395 These data indicate that cells in other tissues when exposed to the hematopoietic microenvironment may have lymphohematopoietic potential. Moreover, marrow contains mesenchymal stem cells capable of giving rise to muscle cells, adipocytes, chondrocytes, and osteocytes396 and cells that give rise to hepatocytes.397 The relationship of these mesenchymal stem cells to lymphohematopoietic stem cells is yet to be elucidated.
EMBRYONIC ORIGIN OF LYMPHOHEMATOPOIETIC STEM CELLS
Controversy exists over the embryonic origin of lymphohematopoietic stem cells, either from the yolk sac or from the aortogonadal mesonephros (AGM) mesenchymal region. One line of study indicates that hematopoietic stem cells originate in murine yolk and from there migrate to fetal liver and then to marrow. Alternatively, a mesenchymal region has been proposed as the source for stem cells for both avian and murine species.399,400,401,402,403,404 and 405 It now appears that during development, there are two temporally separate phases of hematopoiesis, the first in the yolk sac giving rise to primitive hematopoiesis restricted to nucleated embryonic erythrocytes, while definitive hematopoiesis arises later in the aortagonadal mesonephric area, giving rise to all hematopoietic lineages and cells that can repopulate lethally irradiated recipients. A cell bipotential for vascular and hematopoietic lineages, the hemangioblast may give rise to the hematopoietic lineages.406 The yolk sac region may also be a source of some definitive hematopoiesis407 (see Chap. 4 and Chap. 7).
STEM CELL LOCATION AND MODULATION
Hematopoietic stem cells in the adult reside most prominently in the marrow and less so in the spleen. Stem cells are also present in blood, and the number in blood may be dramatically increased by a number of hematopoietic stresses (anemia, endotoxin, infection), by cytotoxic therapy (e.g., cyclophosphamide) or by the administration of a variety of cytokines (most prominently G-CSF, KIT ligand, FLT-3, IL-8, GM-CSF, or thrombopoietin).
STEM CELL PHENOTYPE
The hematopoietic stem cell in both murine and human species has been characterized as to surface protein, physical, metabolic, and cell cycle characteristics and these characteristics used to purify stem cells. Early stem cells express a relatively large number of cytokine receptors at low levels, with a restricted number of receptors expressed at higher levels after differentiation.408 Certain other proteins have been found to be present on relatively primitive classes of stem cells: in the mouse, Ly6, c-Kit, c-mpl, CD34, Thy-1, and Flk-2/Flk-3,371,409,410,411 and 412 and in the human, CD34, c-Kit, Thy-1, Flk-2/Flt-3, and AC133.412,413,414 and 415 Other features of primitive stem cells include lack of expression of HLA-DR, CD38, and differentiated lineage markers.416,417 Human and mouse CD34 negative cells may have significant stem cell potential and give rise to CD34+ cells418,419 or, alternatively, that CD34 expression may vary, depending on the activation state of the stem cell.420 The most primitive stem cells appear to be dormant in G0 or a prolonged G1. The stem cell membrane has a strong p170 membrane pump activity. This pump is the MDR-1 which extrudes certain chemotherapeutic agents and the supravital dyes, rhodamine and Hoechst, from cells.421 Thus the most primitive stem cells are characterized by an absence of lineage markers and low staining with rhodamine and Hoechst.422,423,424 and 425 These properties have been used to purify or selectively enrich stem cells for study and clinical application.
PLURIPOTENTIAL LYMPHOHEMATOPOIETIC (MARROW-REPOPULATING) STEM CELL
This cell is ultimately defined by in vivo repopulation and renewal; as noted above, under the appropriate circumstances a single stem cell may renew and restore hematopoiesis in a mouse.9,10 and 11 Thus the cell has tremendous renewal, proliferation, and differentiation potential. These cells have been characterized most definitively in murine species, where in vivo repopulation or population can be assessed in detail. In humans, of necessity, this cell has been defined by surrogate assays of questionable validity. This cell appears to be quiescent (G0 or prolonged G1). BRDU studies suggesting a constant cycling state for these cells426 may be monitoring DNA damage and repair rather than cell cycling.427 However, the stem cell is easily stimulated to enter active cell cycle transit by in vitro exposure to cytokines428 or by in vivo engraftment.429 This cell also appears to have a high level of baseline motility and is rapidly stimulated to demonstrate directed movement by exposure to a variety of cytokines, perhaps most prominently, stromal-derived factor-1 (SDF-1) and KIT ligand.430 It rapidly binds in vitro to stromal populations,431 expresses a variety of adherence proteins (vide infra), and migrates toward stromal cells. The murine lineage negative, rhodamide low, Hoechst low cells appear to respond to SFD-1 and KIT ligand in the presence of stroma with extension of lamellipodia in up to 10 to 15 percent of cells.430 These cells may also differ from differentiated cells in their adhesion receptor profile.
The stem cell appears capable of renewal and expansion under certain experimental conditions such as MDR-1 transfection,432 or certain serial transfer experiments, but most attempts to expand the engraftable stem cells in vitro, usually in the presence of stroma and/or cytokines, have been unsuccessful.413 There has been intense interest in such approaches for their potential for retroviral vector-based gene therapy or stem cell transplantation.
A critical feature of this cell is its plasticity, especially with cell cycle transit. The engraftment phenotype of this cell varies dramatically and reversibly when stimulated by cytokines (IL-11, IL-3, IL-6, steel factor) to transit the cell cycle.433,434 and 435 During the first cell cycle transit, long-term engraftment appears to be lost in late S-early G2 and regained in G1.435 Multiple other phenotypic features of this cell change with cytokine-induced cell cycle transit, including cytokine and adhesion receptor, transcription factor, and cell cycle factor expression.436,437,438 and 439 The critical observation is that the phenotype of this cell can go from high to low to high engraftment. These observations suggest a cell cycle model of hematopoiesis.
ADHESION PROTEINS AND RECEPTORS
Adhesion receptors and their ligands mediate cell-to-matrix and cell-to-cell interaction and include the selectins, the integrins, the immunoglobulin family, and miscellaneous others. First defined in studies on lymphoid homing, these proteins now have been found to play a role in anchoring of hematopoietic cells in marrow or in the promotion of differentiation.440,441 The integrin class of adhesion receptors are heterodimers of the noncovalently associated a and b chains. There are at least 18 different a and b chains. The b chain associates with a1 through a6 to form the very late antigen (VLA) group. a5b1 is the classical fibrinogen receptor, and a6b1 is a laminin receptor. L-selectin, PECAM-1, CD44, b1, and a4 through a6 are all expressed on primitive human or murine stem cells, and their modulation appears to correlate with engraftment efficiency. Immature blasts, erythroid progenitors, monocytes, and CD34+ cells show a4 and a5, and these decrease with maturation. There also appears to be differential binding of hematopoietic cells to different extracellular matrix components: erythroid cells to fibronectin442,443 and CFU-GM and BFU-E to collagen.444 Several groups have implicated VLA-4 and VCAM-1 or CD44 in marrow homing and engraftment. VLA-4 binding to the CS-1 peptide of alternatively spliced fibronectin mediates binding of murine CFU-S445 or human long-term marrow culture initiating cells,446 and an antibody to VLA-4 caused mobilization of hematopoietic progenitors in normal or cytokine-treated primates or mice.447,448 c-KIT receptor was also found to be important for optimal mobilization by anti-VLA-4 or VCAM-1 in W/Wv or S1/S1d mice.449
The non-integrin adhesion receptors also play a role in engraftment. These include CD44,450 PECAM,451 and a receptor for a ligand bearing galactosyl and mannosyl residues from stroma.452 Both PECAM and L-selectin are affected by cytokines, and hematopoietic progenitors can bind to thrombospondin,453,454 interleukin-3, and KIT ligand,448 and these cytokines bind to heparin sulfate proteoglycans. Studies with E- and P- selectin knockout mice,455 also employing VCAM-1 blocking antibodies, has implicated the selectins and VLA-4 as receptors that are critical for stem cell homing. Adhesion receptor expression on hematopoietic progenitor or stem cells is summarized in Table 14-6.

TABLE 14-6 HEMATOPOIETIC STEM AND PROGENITOR CELL ADHESION RECEPTORS AND LIGAND

STEM CELL HOMING AND THE MICROENVIRONMENT
A critical aspect of hematopoiesis is the milieu in which hematopoietic stem cells reside: the microenvironment. The latter consists of stromal cells and the extracellular matrix. Stem cells home to stromal cells during development, in the steady state, or after transplantation, and these same cells function to regulate hematopoiesis.456,457,458,459 and 460 Early studies showed the dramatic influence of microenvironment in the spleen on lineage expression in spleen colonies,26,27 and 28 and the introduction of the Dexter long-term stromal-based culture system provided an in vitro model of stromal supported hematopoiesis.461,462 In this latter system adherent stromal cells, consisting of hematopoietically derived macrophages, preadipocytic fibroblasts, and other cells (variable with the system) could support virtually all engraftable stem cells, CFUs, and a variety of different progenitor cells.463,464,465 and 466 The marrow stromal cells in this system produce a variety of cytokines and express a number of adhesion molecules, both playing important roles in regulation of lymphohematopoiesis.467,468,469,470 and 471 Adhesion proteins are critical for stem cell binding to stromal cells in vitro and homing to marrow in vivo when stem cells are infused subsequently and move to the endosteal surface of marrow (Chap. 4).472
MOBILIZATION OF STEM OR PROGENITOR CELLS
Long-term repopulating stem cells and their progenitors are mobilized into the blood by a number of cytokines including GM-CSF, CSF-1, IL-1, KIT ligand, FLT-3, IL-11, IL-12, IL-3, IL-8, IL-7, MIP-1a, and epo.473,474,475,476,477,478,479 and 480 In addition, previous exposure to cyclophosphamide or other cytoxic agents also mobilizes stem cell, presumptively as a result of cytokine effects. Mobilization has been utilized to collect stem and progenitor cells for transplantation. Pretreatment with cyclophosphamide followed by treatment with KIT ligand and G-CSF may be the most potent mobilization regimen. In general, mobilized progenitor and stem cells appear to restore hematopoiesis more rapidly than unstimulated marrow, although marrow “primed” with in vivo cytokines may be equivalent to mobilized blood cells for rapid engraftment. Whether these mobilized stem cells will have the same long-term repopulation capacity as marrow cells remains to be established (Chap. 4 and Chap. 141).
CHAPTER REFERENCES

1.
Nakahata T, Ogawa M: Clonal origin of murine hemopoietic colonies with apparent restriction to granulocyte-macrophage-megakaryocyte (GMM) differentiation. J Cell Physiol 111:239, 1982.

2.
Ogawa M, Pharr PN, Suda T: Stochastic nature of stem cell functions in culture. Progress in Clinical & Biological Research, in Hematopoietic Stem Cell Physiology, edited by E Cronkite, N Dainiak, R McCaffrey, J Palek, P Quesenberry, pp 11–19. Alan Liss, New York, 1985.

3.
Suda J, Suda T, Ogawa M: Analysis of differentiation of mouse hemopoietic stem cells in culture by sequential replating of paired progenitors. Blood 64:393, 1984.

4.
Nakahata T, Ogawa M: Hemopoietic colony-forming cells in umbilical cord blood with extensive capability to generate mono- and multipotential hemopoietic progenitors. J Clin Invest 70:1324, 1982.

5.
Nakahata T, Ogawa M: Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc Natl Acad Sci USA 79:3843, 1982.

6.
Suda T, Suda J, Ogawa M: Single-cell origin of mouse hemopoietic colonies expressing multiple lineages in variable combinations. Proc Natl Acad Sci USA 80:6689, 1983.

7.
Suda T, Suda J, Ogawa M: Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc Natl Acad Sci USA 81:2520, 1963.

8.
Becker AF, McCulloch EA, Till JE: Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197:452, 1963.

9.
Wu AM, Till JE, Siminovitch L, McCulloch EA: A cytological study of the capacity for differentiation of normal hemopoietic colony-forming cells. J Cell Physiol 69:177, 1967.

10.
Abramson S, Miller RG, Phillips RA: The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 145:1567, 1977.

11.
Lemischka IR, Raulet DH, Mulligan RC: Developmental potential and dynamic behavior of hematopoietic stem cells. Cell 45:917, 1986.

12.
Harrison DE, Lerner C, Hoppe PC, Carlson GA, Alling D: Large numbers of primitive stem cells are active simultaneously in aggregated embryo chimeric mice. Blood 69:773, 1987.

13.
Till JE, McCulloch EA: A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213, 1961.

14.
Siminovitch L, McCulloch EA, Till JE: The distribution of colony forming cells among spleen colonies. J Cell Comp Physiol 62:327, 1963.

15.
Lewis JP, Trobaugh FE Jr: Hematopoietic stem cells. Nature 204:589, 1964.

16.
Juraskova V, Tkadlecek L: Character of primary and secondary colonies of hematopoiesis in the spleen of irradiated mice. Nature 206:951, 1965.

17.
Quesenberry PJ, Stanley K: A statistical analysis of murine stem cell suicide techniques. Blood 56:1000, 1980.

18.
Moffatt DJ, Rosse C, Yoffey JM: Identity of the hemopoietic stem cell. Lancet 2:547, 1967.

19.
Van Bekkum DW, van Noord MJ, Maat B, Dicke KA: Attempts at identification of hemopoietic stem cell in mouse. Blood 38:547, 1971.

20.
Rubinstein AS, Trobaugh FE Jr: Ultrastructure of presumptive hematopoietic stem cells. Blood 42:61, 1973.

21.
Magli MC, Iscove NN, Odartchenko N: Transient nature of early hematopoietic spleen colonies. Nature 295:527, 1982.

22.
Curry JL, Trentin JJ: Hemopoietic spleen colony studies. I. Growth and differentiation. Dev Biol 15:395, 1967.

23.
Siminovitch LF, Till JE, McCulloch EA: Radiation responses of hemopoietic colony forming cells derived from different sources. Radiat Res 24:482, 1965.

24.
Barnes DW, Loutit JF: Hematopoietic stem cells in the peripheral blood. Lancet 2:1138, 1967.

25.
Wu AM, Till JE, Siminovitch L, McCulloch EA: Cytological evidence for a relationship between normal hematopoietic colony forming cells and cells of the lymphoid system. J Exp Med 127:455, 1968.

26.
Curry JL, Trentin JJ: Hemopoietic spleen colony studies. IV. Phytohemagglutinin and hemopoietic regeneration. J Exp Med 126:819, 1967.

27.
Fowler JH, Wu AM, Till JE, et al: The cellular composition of hemopoietic spleen colonies. J Cell Physiol 69:65, 1967.

28.
Pluznik DH, Sachs L: The cloning of normal “mast” cells in tissue culture. J Cell Physiol 66:319, 1965.

29.
Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287, 1966.

30.
Reissman KR: Studies on the mechanisms of rats during hypoxia. Blood 5:372, 1950.

31.
Erslev AJ: Humoral regulation of red cell production. Blood 8:349, 1953.

32.
Cotes PM, Bangham DR: Bioassay of erythropoietin in mice made polycythemic by exposure to air at a reduced pressure. Nature 191:1065, 1961.

33.
Jacobson LO, Goldwasser E, Plzak L, et al: Studies on erythropoiesis. IV. Reticulocyte response of hypophysectomized and polycythemic rodents to erythropoietin. Proc Soc Exp Biol 94:243, 1957.

34.
Plzak LF, Fried W, Jacobson LO, et al: Demonstration of stimulation of erythropoiesis by plasma from anemic rats using Fe59. J Lab Clin Med 46:671, 1955.

35.
Axelrad AA, McLeod DL, Shreeve MM, Health DS: Properties of cells that produce erythrocytic colonies in vitro, in Hemopoiesis in Culture: Second International Workshop, edited by WA Robinson, p 226. HEW Publication, NIH Government Printing Office, Washington, 1973.

36.
McLeod DL, Shreeve MM, Axelrad AA: Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E. Blood 44:517, 1974.

37.
Iscove NN, Sieber F: Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol 3:32, 1975.

38.
D’Andrea AD, Lodish HF, Wong GG: Expression cloning of the murine erythropoietin receptor. Cell 57:277, 1989.

39.
Sawyer ST, Krantz SB, Goldwasser E: Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262:5554, 1987.

40.
Koury MJ, Bondurant MC: Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 137:65, 1988.

41.
Koury MJ, Bondurant MC: A survival model of erythropoietin action. Blood 74(suppl 1):48a, 1989.

42.
Dinarello CA: Interleukin-1. Rev Infect Dis 6:51, 1984.

43.
Dinarello CA: Biology of interleukin-1. FASEB J 2:108, 1988.

44.
Smith KA: Interleukin-2, inception, impact and implications. Science 240:1169, 1988.

45.
Naldini A, Fleischmann WR, Ballas ZK, et al: Interleukin-2 inhibits in vitro granulocyte macrophage colony formation. J Immunol 139:1880, 1987.

46.
Burdach SE, Levitt LJ: Receptor specific inhibition of bone marrow erythropoiesis by recombinant DNA-derived interleukin-2. Blood 69:1368, 1987.

47.
Metcalf D, Bagby GC, Johnson GR, et al: Effects of purified bacterially synthesized murine multi-colony stimulating factor (interleukin-3) on hematopoiesis in normal adult mice. Blood 68:46, 1986.

48.
Broxmeyer HE, Williams DE, Cooper S, et al: Comparative effects in vivo of recombinant murine interleukin-3, natural murine colony stimulating factor-1 and recombinant murine granulocyte-macrophage colony stimulating factor on myelopoiesis in mice. J Clin Invest 79:721, 1987.

49.
Ihle JN: Biochemical and biological properties of interluekin-3: a lymphokine mediating the differentiation of a lineage of cells which includes prothymocytes and mast-like cells. J Immunol 131:282, 1983.

50.
Clark SC, Kamen R: The human hematopoietic colony-stimulating factors. Science 236:1229, 1987.

51.
Howard M, Farrar J, Hilfiker M, et al: Identification of a T cell derived B cell growth factor distinct from interleukin-2. J Exp Med 155:914, 1982.

52.
Vitetta ES, Brooks K, Chen YW, et al: T cell derived lymphokines that induce IgM and IgG secretion in activated murine B cells. Immunol Rev 78:137, 1984.

53.
Campbell HD, Tucker WQJ, Hort Y, et al: Molecular cloning and expression of the gene encoding human eosionophil differentiation factor (interleukin-5). Proc Natl Acad Sci USA 84:6629, 1987.

54.
Van Damme J, DeLey M, Van Snick J, et al: The role of interferon-B1 and the 26-kDa protein (interferon-B2) as mediators of the antiviral effect of interleukin-1 and tumor necrosis factor. J Immunol 139:1867, 1987.

55.
Hirano T, Taga T, Yasukawa K, et al: Human B cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 84:228, 1987.

56.
Yasukawa K, Hirano T, Watanabe Y, et al: Structure and expression of human B cell stimulatory factor 2 (BSF-2) gene. EMBO J 6:2939, 1987.

57.
Wong GG, Witek-Giannotti JS, Temple PA, et al: Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol 40:3040, 1988.

58.
Namen AE, Lupton S, Hjerrild K, et al: Stimulation of B cell progenitors by cloned murine interleukin-7. Nature 333:571, 1988.

59.
Namen AE, Schmierer AE, March CJ, et al: B cell precursor growth-promoting activity: Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 167:988, 1988.

60.
Yoshimura T, Matsushima K, Tanaka S, et al: Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233, 1987.

61.
Shroder JM, Mrowietz U, Morita E, Christophers E: Purification and partial biochemical characterization of a human monocyte-derived neutrophil-activating peptide that lacks interleukin-1 activity. J Immunol 139:3474, 1987.

62.
Lindley I, Aschauer H, Seifert J-M, et al: Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc Natl Acad Sci USA 85:9199, 1988.

63.
Kimberly JVZ, Fischer E, Hawes AS, et al: Effects of intravenous IL-8 administration in nonhuman primates. J Immunol 148:1746, 1992.

64.
Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K: Properties of the novel pro-inflammatory super gene “intercrine” cytokine family. Ann Rev Immunol 9:617, 1991.

65.
Holbrook ST, Ohls RK, Schibler KR, et al: Effect of interleukin-9 on clonogenic maturation and cell cycle status of fetal and adult hematopoietic progenitors. Blood 77:2129, 1991.

66.
Thompson-Sniper LA, Dhar V, Bond M, et al: Interleukin-10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 173:507, 1991.

67.
Paul SR, Yang Y-C, Donahue RE, et al: Stromal cell-associated hematopoiesis: Immortalization and characterization of a primate bone marrow-derived cell line. Blood 77:1723, 1991.

68.
Paul SR, Bennett F, Calbretti JA, et al: Molecular cloning of a cDNA encoding interleukin-11, a stromal lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87:7512, 1990.

69.
Musashi M, Yang Y-C, Paul SR: Direct and synergistic effects of interleukin-11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA 88:765, 1991.

70.
Gubler U, Chua AO, Schoenhaut DS, et al: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88:4143, 1991.

71.
Minty A, Chalon P, Derocq JM, et al: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248, 1993.

72.
Ambrus JL, Pippin J, Joseph A, et al: Identification of a cDNA for a human high-molecular-weight B cell growth factor. Proc Natl Acad Sci USA 90:6330, 1993.

73.
Agostini C, Trentin L, Sancetta R, et al: Interleukin-15 triggers activation and growth of the CD-8 T cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome. Blood 90: 1115, 1997.

74.
Baier M, Bannert N, Werner A, Lang K, Kurth R: Molecular cloning, sequence, expression, and processing of the interleukin-16 precursor. Proc Natl Acad Sci USA 94:5273, 1997.

75.
Fossiez F, Djossou O, Chomarat P, et al: T cell IL-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183: 2593, 1996.

76.
Yao Z, Painter SL, Fanslow WC, et al: Human IL-17: a novel cytokine derived from T cells. J Immunol 155: 5483, 1995.

77.
Micallef MJ, Ohtsuki T, Kohno K, et al: Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 26: 1647, 1996.

78.
Okamura H, Tsutsi H, Komatsu T, et al: Cloning of a new cytokine that induces INF-gamma production by T cells. Nature 378: 88, 1995.

79.
Waheed A, Shadduck R: Purification and properties of L cell-derived colony-stimulating factor. J Lab Clin Med 94:180, 1979.

80.
Stanley ER, Guilbert LF: Methods of purification, assay, characterization and target cell binding of a colony-stimulating factor (CSF-1). J Immunol Meth 42:253, 1981.

81.
Nicola NA, Metcalf D, Matsumoto M, et al: Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony stimulating factor. J Biol Chem 258:9017, 1983.

82.
Nicola NA, Begley CG, Metcalf D: Identification of the human analogue of a regulator that induces differentiation in murine leukemia cells. Nature 314:625, 1985.

83.
Sieff CA, Emerson SF, Donahue RE, Nathan DG: Human recombinant granulocyte-macrophage colony stimulating factor: a multilineage hematopoietic. Science 230:1171, 1985.

84.
Metcalf D, Burgess AW, Johnson GR, et al: In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli. Comparison with purified native GM-CSF. J Cell Physiol 128:421, 1986.

85.
Robinson BE, McGrath HE, Quesenberry PJ: Recombinant murine granulocyte-macrophage colony stimulating factor has megakaryocyte colony stimulating activity and augments megakaryocyte colony stimulation by interleukin-3. J Clin Invest 79:1648, 1987.

86.
Quesenberry PJ, Ihle JN, McGrath HE: The effect of interleukin-3 and GM-CSA-2 on megakaryocyte and myeloid clonal colony formation. Blood 65:214, 1985.

87.
Stanley IJ, Burgess AW: Granulocyte-macrophage colony stimulating factor stimulates the synthesis of membrane and nuclear proteins in murine neutrophils. J Cell Biochem 23:241, 1983.

88.
Eaves AC, Eaves CJ: Erythropoiesis in culture. Clin Haematol 13:371, 1984.

89.
Gregory CJ, Eaves AC: Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biological properties. Blood 51:527, 1978.

90.
Lyman DJ, James L, Vanden BT, et al: Molecular cloning of ligand for fH3/flk-2 tyrosine kinase receptor: a proliferative factor. Cell 75:1157, 1993.

91.
Lyman S, Jacobson S: C-kit ligand and FLT-3 ligand: stem progenitor cell factors with overlapping yet distinct activities. Blood 91:1101, 1998.

92.
Strobl H, Bello-Fernandez C, Riedl E, et al: FLT-3 ligand in cooperation with transforming growth factor-61 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425, 1997.

93.
Maraskovsky E, Brasel K, Teepe M, et al: Dramatic increase in the numbers of functionally mature dendritic cells in FT-3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184:1993, 1996.

94.
Lynch DH, Andersen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL: FLT-3 ligand induces tumors regression and antitumor immune responses in vivo. Nat Med 3:625, 1997.

95.
Toksoz D, Zsebo KM, Smith KA, et al: Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human hematology of the steel gene product, stem cell factor. Proc Natl Acad Sci USA 89:7350, 1992.

96.
Lowry PA, Zsebo KM, Deacon DH, Eichman CE, Quesenberry PJ: Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA+Lin- murine hematopoietic progenitors. Exp Hematol 19:994, 1991.

97.
Lowry PA, Deacon DH, Witefield P, McGrath HE, Quesenberry PH: SCF induction of in vitro murine hematopoietic colony formation by “subliminal” cytokine combinations: the role of “anchor factors.” Blood 80:663-669, 1992.

98.
De Savvage FJ, Carver-Moore K, Luoh S, et al: Physiological regulation of early and late stages of megakaryocyteopoiesis by thrombopoietin. J Exp Med 183:651, 1996.

99.
Kaushanksy K, Lin N, Grossman A, Homen J, Sprugel KH, Brouchy VC: Thrombopoietin expands erythroid granulocyte and macrophage and megakarocyte progenitor cells in normal and myelosuppressed mice. Exp Hematol 23:265, 1996.

100.
Plumb M, Graham GJ. Grove M, Reid A, Pragnell IB: Molecular aspects of a negative regulator of haemopoiesis. Br J Cancer 64:990, 1991.

101.
Broxmeyer HE, Sherry B, Lu L, Cooper S, Oh K-O, Tekamp-Olson P, Kwon BS, Corami A: Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood 76:1110, 1998.

102.
Broxmeyer HE: Suppressor cytokines and regulation of myelopoiesis. Am J Ped Hematol/Oncol 14:22, 1992.

103.
Keller JR, McNeice IK, Sill KT, et al: Transforming growth factor-beta directly regulates primitive murine hematopoietic cell proliferation. Blood 75:596, 1990.

104.
Jacobsen SEW, Veiby OP, Myklebust J, Okkenhaug C, Lyman SD: Ability of FLT-3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitor is potentially and directly inhibited by transforming growth factors-b and tumor increases factor-a. Blood 87:5010, 1996.

105.
Broxmeyer HE, Lu L, Cooper S, Schwa RH, Mason AJ, Nikolias K: Selective and indirect modulation of human multi-potential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc Natl Acad Sci USA 85:9052, 1998.

106.
Laerum OD, Paukovits WR: Inhibitory effects of a synthetic pentapeptide on hemopoietic stem cells in vitro and in vivo. Exp Hematol 12:7, 1984.

107.
Bonnet D, Cesaire R, Lamoine F, et al: The tetrapeptide AcSDKP an inhibitor of the cell cycle status for normal human hematopoietic progenitors, has no effect on leukemia cells. Exp Hematol 20:251, 1992.

108.
Moreau JF, Donaldson DD, Bennet F, et al: Leukemia inhibitory factor is identical to the myeloid growth factor human interleukin for DA cells. Nature 336:690, 1988.

109.
Fletcher FA, Williams DE, Maliszewski C, et al: Murine leukemia inhibitory factor enhances retroviral-vector infection efficiency of hematopoietic progenitors. Blood 76:1098, 1990.

110.
Kurtz A, Jelkman W, Bauer C: A new candidate for the regulation of erythropoiesis-insulin-like growth factor-1. FEBS Lett 149:105, 1982.

111.
Merchav S, Tatarsky I, Hochberg Z: Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor-I/Somatomedin C and human growth hormone. J Clin Invest 81:791, 1988.

112.
Kmiecik TE, Keller JR, Rosen E, Vandewoude GF: Hepatocyte growth factor is a synergistic factor for growth of hematopoietic progenitor cells. Blood 80:2454, 1992.

113.
Wilson EL, Rifkin DB, Kelly T, et al: Basic fibroblast growth factor stimulates myelopoiesis in long-term human bone marrow cultures. Blood 77:954, 1991.

114.
Gabbianelli M, Sargiacomo M, Pelesi E, et al: “Pure” human hematopoietic progenitors: permissive action of basic fibroblast growth factor. Science 249:1561, 1990.

115.
Bruno E, Cooper RJ, Wilson EL, et al: Basic fibroblast growth factor promotes the proliferation of human megakaryocyte progenitor cells. Blood 82:430, 1993.

116.
Xia-Qiang Y, Brady G, Iscove NN: Platelet-derived growth factor (PDGF) activates primitive hematopoietic precursors (pre-CFC multi) by upregulating IL-1 in PDGF receptor expressing macrophages. J Immunol 150:2440, 1993.

117.
Miyake T, Kung CKH Goldwasser E: Purification of human erythropoietin. J Biol Chem 252:5558, 1977.

118.
Jacobs K, Shoemaker C, Rudersdorf R, et al: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806, 1985.

119.
Lai PH, Everett R, Wang FF, et al: Structural characterization of human erythropoietin. J Biol Chem 261:3116, 1986.

120.
Jacobson LO, Goldwasser E, Fried W, et al: Role of the kidney in erythropoiesis. Nature 179:633, 1957.

121.
Koury ST, Bondurant MC, Koury MK: Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71:524, 1988.

122.
Lacombe C, DaSilva JL, Bruneval P: Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81:620, 1988.

123.
Maxwell AP, Lappin TRJ, Johnson CF, et al: Erythropoietin production in kidney tubular cells. Br J Haematol 74:535, 1990.

124.
Jacobson LO, Marks EK, Gaston EO, et al: Studies on erythropoiesis. XI. Reticulocyte response of transfusion induced polycythemic mice to anemic plasma from nephrectonized mice and to plasma from nephrectonized rate exposed to low oxygen. Blood 14:635, 1959.

125.
Fried W: The liver as a source of extrarenal erythropoietin. Blood 40:671, 1972.

126.
Mirand EA, Murphy GP, Steeves RA, et al: Extrarenal production of erythropoietin in man. Acta Haematol 39:359, 1968.

127.
Naets JP, Witteck M: Presence of erythropoietin in the plasma of one anephric patient. Blood 31:249, 1968.

128.
Fried W, Baronc-Varelas J, Morley C: Factors that regulate extrarenal erythropoietin production. Blood Cells 10:287, 1984.

129.
Rich IN, Hart W, Kubanek B: Extrarenal erythropoietin production by macrophages. Blood 60:1007, 1982.

130.
Goldberg MA, Dunning SP, Bunn HF: Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242:1412, 1988.

131.
Iscove NN: The role of erythropoietin in regulation of population size and cell cycling of early and late erythroid precursors in mouse bone marrow. Cell Tissue Kinet 10:323, 1977.

132.
Iscove NN: Erythropoietin-independent stimulation of early erythropoiesis in adult marrow cultures by conditioned medium from lectin-stimulated mouse spleen cells, in ICN-UCLA Symposium on Hematopoietic Cell Differentiation, edited by DW Golde, MJ Cline, D Metcalf, et al. Academic Press, New York, 1978.

133.
Zuckerman K, Sullivan R, Quesenberry PJ: Effects of actinomycin-D in vivo on murine erythroid stem cells. Blood 51:957, 1978.

134.
Nihof W, Wierenga PK, Sahr K, et al: Induction of globin mRNA transcription by erythropoietin in differentiating erythroid precursor cells. Exp Hematol 15:779, 1987.

135.
Glass J, Lavidor LM, Robinson SH: Use of cell separation and short term culture techniques to study erythroid cell development. Blood 46:705, 1975.

136.
Landschulz KT, Noyes AN, Rogers O, et al: Erythropoietin receptors on murine erythroid colony forming units: natural history. Blood 137:65, 1988.

137.
Migliaccio G, Migliaccio AR, Visser JW: Synergism between erythropoietin and interleukin-3 in the induction of hematopoietic stem cell proliferation and erythroid burst colony formation. Blood 72:944, 1988.

138.
Umemura T, Papayannopoulou T, Stamatoyannopoulos G: The mechanism of expansion of late erythroid progenitors during erythroid regeneration: Target cells and effect of erythropoietin and interleukin-3. Blood 73:1993, 1989.

139.
Sonoda Y, Yang YC, Wong GG, et al: Erythroid burst-promoting activity of purified recombinant human GM-CSF and interleukin-3: studies with anti-GM-CSF and anti-IL-3 sera and studies in serum free culture. Blood 72:1381, 1988.

140.
Donahue RE, Yang YC, Clark SC: Human P40 T cell growth factor (interleukin-9) supports erythroid colony formation. Blood 72:2271, 1990.

141.
Peschel C, Paul WE, Ohara J, Green I: Effects of B-cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. Blood 70:254-263, 1987.

142.
Burgess AW, Camarakis J, Metcalf D: Purification and properties of colony stimulating factor from mouse lung-conditioned medium. J Biol Chem 252:1998, 1977.

143.
Gasson JC, Weisbart RH, Kaufman SE, et al: Purified human granulocyte-macrophage colony stimulating factor: direct action on neutrophils. Science 226:1339, 1984.

144.
Gough NM, Gough J, Metcalf D, et al: Molecular cloning of cDNA encoding a murine hematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 309:763, 1984.

145.
Lee F, Yokota T, Otsuka T, et al: Isolation of cDNA for a human granulocyte-macrophage colony stimulating factor by functional expression in mammalian cells. Proc Natl Acad Sci USA 82:4360, 1985.

146.
Wong GG, Witek JS, Temple PA, et al: Human GM-CSF: molecular cloning of complementary DNA and purification of the natural and recombinant proteins. Science 228:810, 1985.

147.
Huebner K, Iscobe M, Croce CM, et al: The human gene encoding GM-CSF is a 5121-q32, the chromosome region deleted in the 5q-anomaly. Science 230:1282, 1985.

148.
LeBeau MM, Westbrook CA, Diaz MO, et al: Evidence for the involvement of GM-CSF and fms in the deletion (5q) in myeloid disorders. Science 231:984, 1986.

149.
Chan JY, Slaman DF, Nimer SD, et al: Regulation of expression of human granulocyte/macrophage colony stimulating factor. Proc Natl Acad Sci USA 83:8669, 1986.

150.
Arnaout MA, Wang EA, Clark SC, et al: Human recombinant granulocyte-macrophage colony stimulating factor increases cell to cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 78:597, 1986.

151.
Fleischman J, Golde DW, Weisbart RH, Gasson JC: Granulocyte-macrophage colony stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 68:708, 1986.

152.
Metcalf D, Begley CG, Johnson GR: Biologic properties in vitro of a recombinant human granulocyte-macrophage colony stimulating factor. Blood 67:37, 1986.

153.
Vadas MA, Nicola NA, Metcalf D: Activation of antibody dependent cell mediated cytotoxicity of the human neutrophils and eosinophils by separate colony stimulating factors. J Immunol 130:795, 1983.

154.
Handman E, Burgess AW: Stimulation by granulocyte-macrophage colony stimulating factor of Leishmania tropica killing by macrophages. J Immunol 122:1134, 1979.

155.
Begley CG, Lopez AF, Nicola NA, et al: Purified colony stimulating factors enhance the survival of human neurophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 68:162, 1986.

156.
Weisbart RH, Golde DW, Clark SC, et al: Human granulocyte-macrophage colony stimulating factor is a neutrophil activator. Nature 314:361, 1985.

157.
Dispersio J, Billing P, Kaufman S, et al: The human GM-CSF receptor: Mechanisms of tranmembrane signaling and neutrophil priming. Blood 70:170a, 1987.

158.
Walker F, Nicola NA, Metcalf D, et al: Hierarchical down-modulation of hemopoietic growth factor receptors. Cell 43:269, 1985.

159.
Walker F, Burgess AW: Specific binding of radio-iodinated granulocyte-macrophage colony stimulating factor to hemopoietic cells. EMBO J 4:933, 1985.

160.
Park LS, Friend D, Gillis S, Urdal DL: Characterization of the cell surface receptor for human granulocyte/macrophage colony stimulating factor. J Exp Med 164:251, 1986.

161.
Pluznik DH, Cunningham RE, Noguchi PD: Colony stimulating factor (CSF) controls proliferation of CSF-dependent cells by acting during G1 phase of cell cycle. Proc Natl Acad Sci USA 81:7451, 1984.

162.
Donahue R, Wang E, Stone D, et al: Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 321:872, 1986.

163.
Metcalf D, Bagby CG, Williamson DF, et al: Hemopoietic responses in mice injected with purified recombinant murine granulocyte-macrophage colony stimulating factor. Exp Hematol 15:1, 1987.

164.
Monroe RL, Skelly RR, Taylor P, et al: Recovery from severe hematopoietic suppression using recombinant human graulocyte-macrophage colony-stimulating factor. Exp Hematol 16:344, 1988.

165.
Nienhaus AW, Donahue RE, Karlsson S, Clark SC, et al: Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest 80:573, 1987.

166.
Monray RL, Skelly RR, MacVittie TJ, et al: The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood 70:1696, 1987.

167.
Mayer P, Lam C, Obenhaus H, et al: Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Blood 70:206, 1987.

168.
Welte K, Bonilla MA, Gillo AP, et al: Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal cyclophosphamide-treated primates. J Exp Med 165:941, 1987.

169.
Groopman JE, Mitsuasu RT, Deleo MJ, et al: Effect of recombinant human granulocyte-macrophage colony stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317:593, 1987.

170.
Antman K, Griffin J, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593, 1988.

171.
Grosh WW, Quesenberry PJ: Recombinant human hematopoietic growth factors in the treatment of cytopenias. Clin Immunol Immunopathol 62:S25, 1992.

172.
Tsuchiya M, Asano S, Kaziro Y, Nagata S: Isolation and characterization of the cDNA for murine granulocyte colony stimulating factor. Proc Natl Acad Sci USA 83:7633, 1986.

173.
Nagata S, Tsuchiymec, Asano S, et al: The chromosomal gene structure and two mRNAs for human granulocyte colony stimulating factor. Embo J 5:575, 1989.

174.
Simmers RN, Webber LM, Shannon MF, et al: Localization of the G-CSF gene on chromosome 17 proximal to the breakpoint in the t(15;17) in acute promyelocytic leukemia. Blood 70:330, 1987.

175.
Woodward TA, McNeice IK, Witte PL, et al: Further studies on growth factor production by the TC-1 stromal cell line: pre-B stimulating activity. Blood 75:2130, 1990.

176.
Avalos BR, Hedzat C, Baldwin GC, et al: Biological activities of human G-CSF and characterization of the human G-CSF receptor. Blood 70:165a, 1987.

177.
Vallenga E, Young DC, Wagner K, et al: The effects of GM-CSF and G-CSF in promoting growth of clonogenic cell in acute myeloblastic leukemia. Blood 69:1771, 1987.

178.
Miyauchi J, Kelleher CA, Yang Y, et al: The effects of three recombinant growth factors IL-3, GM-CSF and G-CSF on the blast cells of acute myeloblastic leukemia maintained in short term suspension culture. Blood 70:657, 1987.

179.
Okabe T, Takaku F: In vivo granulocytopoietic activities of human recombinant granulocyte colony stimulating factor. Exp Hematol 14:475, 1986.

180.
Moore MAS, Welte K, Gabrilove JL, et al: In vivo action of recombinant human G-CSF in chemotherapy or radiation myelosuppressed mice. Blood 69:173a, 1986.

181.
Cohen AM, Zsebo K, Hines D, et al: In vivo activity of recombinant human granulocyte colony stimulating factor. Exp Hematol 14:489, 1986.

182.
Welte K, Bonilla MA, Gillio AP, et al: In vivo effects of combined recombinant human G-CSF and GM-CSF on hematopoiesis in primates. Blood 68:183a, 1986.

183.
Monroe RL, Skelly RR, MacVittie TJ, et al: The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood 70:1696, 1987.

184.
Welte K, Bonilla MA, Gabrilove JL, et al: Recombinant human granulocyte-colony stimulating factor: in vitro and in vivo effects on myelopoiesis. Blood Cells 13:17, 1987.

185.
Tamura M, Hattori K, Nomura H, et al: Induction of neutrophilic granulocytosis in mice by administration of purified human granulocyte colony stimulating factor (G-CSF). Biochem Biophys Res Comm 142:454, 1987.

186.
Shimamura M, Kobayashi Y, You A, et al: Effect of human recombinant granulocyte colony stimulating factor on hematopoietic injury in mice induced by 5-fluorouracil. Blood 69:353, 1987.

187.
Gabrilove J, Jakubowski A, Fain K, et al: A Phase I/II study or rhG-CSF in cancer patients at risk for chemotherapy induced neutropenia. Blood 70:135a, 1987.

188.
Bronchud MH, Scarffe JH, Thatcher N, et al: Phase I/II study of recombinant human granulocyte colony stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809, 1987.

189.
Tushinski RJ, Stanley ER: The regulation of mononuclear phagocyte entry into S phase by the colony stimulating factor, CSF-1. J Cell Physiol 122:221, 1985.

190.
Tushinski RJ, Stanley ER: The regulation of macrophage protein turnover by a colony stimulating factor (CSF-1). J Cell Physiol 116:67, 1983.

191.
Wing EJ, Waheed A, Shadduck R, et al: Effect of colony stimulating factor on murine macrophages. J Clin Invest 69:270, 1982.

192.
Wing EF, Ampel NM, Waheed A, et al: Macrophage CSF (M-CSF) enhances the capacity of murine macrophages to secrete oxygen reduction products. J Immunol 135:2052, 1985.

193.
Lin HS, Gordon S: Secretion of plasminogen activator by bone marrow derived mononuclear phagocytes and its enhancement by colony stimulating factor. J Exp Med 150:231, 1979.

194.
Hamilton JA, Stanley ER, Burgess AW, et al: Stimulation of macrophage plasminogen activator activity by colony stimulating factors. J Cell Physiol 103:435, 1980.

195.
Chen BD-M, Lin HS: Colony stimulating factor (CSF-1): Its enhancement of plasminogen activator production and inhibition of cell growth in a mouse macrophage cell line. J Immunol 132:2955, 1984.

196.
Moore RN, Oppenheim JJ, Farrar JJ, et al: Production of lymphocytes-activating factor (interleukin-1) by macrophages activated with colony stimulating factors. J Immunol 125:1302, 1980.

197.
Sherr CF, Rettenmier CW, Sacca R, et al: The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41:665, 1985.

198.
Sacca R, Stanley ER, Sherr CJ, et al: Specific binding of the mononuclear phagocyte colony stimulating factor CSF-1 to the product of the c-fms oncogene. Proc Natl Acad Sci USA 8:3331, 1986.

199.
Rettenmier CW, Sacca R, Furman WL, et al: Expression of the human c-fms proto-oncogene product (colony stimulating factor-1) receptor on peripheral blood mononuclear cells and choriocarcinoma cell lines. J Clin Invest 77:1740, 1986.

200.
Jubinsky PT, Stanley ER: Purification of hemopoietin 1: A multilineage hemopoietic growth factor. Proc Natl Acad Sci USA 82:2764, 1985.

201.
Mochizuki DY, Eisenman JR, Conlon PJ, et al: Interleukin-1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci USA 84:5267, 1987.

202.
Matsushima H, Roussel MF, Ashman RA, Scherr CJ: Colony-stimulating factor-1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701, 1991.

203.
Stanley ER, Heard PM: Factors regulating macrophage production and growth. Purification and some properties of the colony stimulating factor from medium. J Biol Chem 252:4305, 1977.

204.
Waheed A, Shadduck R: Purification of colony-stimulating factor by affinity chromatography. Blood 60:238, 1982.

205.
Das Sk, Stanley ER, Guilbert LF, Forman LW: Human colony stimulating factor (CSF-1) radioimmunoassay: resolution of three subclasses of human colony stimulating factors. Blood 58:630, 1981.

206.
Das SK, Stanley ER: Structure-function studies of a colony stimulating factor (CSF-1). J Biol Chem 257:13679, 1982.

207.
Kawaski ES, Lander MB, Wang AM, et al: Molecular cloning of a complementary DNA encoding human macrophage-specific colony stimulating actor (CSF-1). Science 230:291, 1985.

208.
DeLamarter JF, Hession C, Semon D, et al: Nucleotide sequence of a cDNA encoding murine CSF-1 (macrophage-CSF). Nucleic Acid Res 15:2389, 1987.

209.
Price LKH, Choi HU, Kosenberg L, Stanley ER: The predominant form of secreted colony stimulating factor-1 is a proteoglycan. J Biol Chem 267:2190, 1992.

210.
Ihle JN, Keller J, Henderson L, et al: Procedures for the purification of IL-3 to homogeneity. J Immunol 129:2431, 1982.

211.
Clark Lewis I, Kent SBH, Schrader JW: Purification to apparent homogeneity of a factor stimulating the growth of multiple lineages of hemopoietic cells. J Biol Chem 259:7488, 1984.

212.
Prestidge RL, Watson JD, Urdal DL, et al: Biochemical comparison of murine colony stimulating factors secreted by a T cell lymphoma and a myelomonocytic leukemia. J Immunol 133:293, 1984.

213.
Cutler RL, Metcalf D, Nicola NA, et al: Purification of a multipotential colony stimulating factor from pokeweed mitogen-stimulated mouse spleen cell conditioned medium. J Biol Chem 260:6579, 1985.

214.
Watson JD, Crosier PS, March CF, et al: Purification to homogeneity of a human hematopoietic growth factor that stimulates the growth of a murine IL-3-dependent cell line. J Immunol 137:854, 1986.

215.
Fung MC, Hapel AJ, Ymer S, et al: Molecular cloning of cDNA for murine interleukin-3. Nature 307:233, 1984.

216.
Yokota T, Lee F, Rennick D, et al: Isolation and characterization of a mouse cDNA clone that expresses mast cell growth factor activity in monkey cells. Proc Natl Acad Sci USA 81:1070, 1984.

217.
Miyatake S, Yokota T, Lee F, Arai K: Structure of the chromosomal gene for murine interleukin-3. Proc Natl Acad Sci USA 82:316, 1985.

218.
Campbell HD, Ymer S, Fung M-C, Young IG: Cloning and nucleotide sequence of the murine interleukin-3 gene. Eur J Biochem 150:297, 1985.

219.
Todokoro K, Yamamoto A, Amanuma H, Ikawa Y: Isolation and characterization of a genomic DDD mouse interleukin-3 gene. Gene 39:103, 1985.

220.
Hapel AJ, Osborne JM, Fung MC, et al: Expression of 20-hydroxysteroid dehydrogenase in mouse macrophages, hemopoietic cells and cell lines and its induction by colony stimulating factors. J Immunol 134:2492, 1985.

221.
Prystowsky MB, Ihle JN, Rich I, et al: Two biologically distinct colony stimulating factors are secreted by a T lymphocyte clone. J Cell Biochem 6:37, 1983.

222.
McNiece IK, Bertoncello I, Kriegler AB, Quesenberry PJ: Colony forming cells with high proliferative potential (HPP-CFC). Int J Cell Cloning 8:146, 1990.

223.
Koike K, Ihle JN, Ogawa M: Declining sensitivity to interleukin 3 of murine multipotential hemopoietic progenitors during their development. Application to a culture system that favors blast cell colony formation. J Clin Inv 77:894, 1986.

224.
Broxmyer HE, Williams DE, Hangoc G, et al: Synergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine colony stimulating facotr-1, recombinant murine interleukin-3 and recombinant murine granulocyte/macrophage colony stimulating factor. Proc Natl Acad Sci USA 84:3871, 1987.

225.
Donahue RE, Seehra J, Metzger M, et al: Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241:1820, 1988.

226.
Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in a plastic anemia. Blood 76:1287, 1990.

227.
Kuzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241, 1991.

228.
Arend WP, Welgus HG, Thompson RC, Eisenbery SP: Biologic properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 85:1694, 1990.

229.
Dinarello CA: Interleukin-1 and the pathogenesis of the acute phase response. N Engl J Med 311:1413, 1984.

230.
Ikebuchi K, Ihle JN, Hirai Y, et al: Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6 and granulocyte colony stimulating factor. Blood 72:2007, 1988.

231.
Hoang T, Haman A, Goncalves O, et al: Interleukin-1 enhances growth factor-dependent proliferation of the clonogenic cells in acute myeloblastic leukemia and of normal human primitive hemopoietic precursors. J Exp Med 168:463, 1988.

232.
Zhou Y-Q, Stanley ER, Clark SC, et al: Interleukin-3 and interleukin-1-alpha allow earlier bone marrow progenitors to respond to human colony stimulating factor-1. Blood 72:1870, 1988.

233.
Zsebo KM, Wypych J, Yuschenkoff VN, et al: Effects of hematopoietin-1 and interleukin-1 activities on early hematopoietic cells of the bone marrow. Blood 71:962, 1988.

234.
Warren DJ, Moore MAS: Synergism amon interleukin-1, interleukin-3 and interleukin-5 in the production of eosinophils from primitive hemopoietic stem cells. J Immunol 140:94, 1989.

235.
Kupper TS, Lee F, Birchall N, et al: Interleukin-1 binds to specific receptors on human keratinocytes and induces granulocyte-macrophage colony stimulating factor mRNA and protein. J Clin Invest 82:1787, 1988.

236.
Seelentag WK, Mermod J-J, Montesano R, Vassalli P: Additive effects of interleukin-1 and tumor necrosis factor-alpha on the accumulation of the three granulocytes and macrophage colony stimulating factor mRNAs in human endothelial cells. EMBO J 6:2261, 1987.

237.
Hermann F, Oster W, Meuer SC, et al: Interleukin-1 stimulates T lymphocytes to produce granulocyte-monocyte colony stimulating factor. J Clin Invest 81:1415, 1988.

238.
Fibbe WE, Van Damme J, Billiou A, et al: Interleukin-1 stimulates T lymphocytes to produce granulocyte-monocyte colony stimulating factor. J Clin Invest 81:1415, 1988.

239.
Zucali JR, Dinarello CA, Oblon DF, et al: Interleukin-1 stimulates fibroblasts to produce granulocyte-macrophage colony stimulating activity and prostaglandin E2. J Clin Invest 77:1857, 1986.

240.
Rennick D, Yang G, Gemmell L, Lee F: Control of hemopoiesis by a bone marrow stromal cell clone: lipopolysaccharide and interleukin-1 inducible production of colony stimulating factors. Blood 69:682, 1987.

241.
Kimura H, Ishibashi T, Shikama Y, et al: Interleukin-1b (IL-1b) induces thromobocytosis in mice: possible implication of IL-6. Blood 76:2493, 1990.

242.
Crown J, Jakubowski A, Kemeny N, et al: A phase I trial of recombinant human interleukin-1b alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78:1420, 1991.

243.
Waldman TA, Goldman CK, Robb RJ, et al: Expression of interleukin-2 receptors on activated human B cell. J Exp Med 160:1450, 1984.

244.
Noma Y, Sideras P, Naito T, et al: Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature 319:640, 1986.

245.
Coffman RL, Ohara J, Bond MW, et al: B cell stimulatory factor-1 enhances the IgE response of lipoplysacchardie-activated B cells. J Immunol 136:4538, 1986.

246.
Broxmeyer HE, Lu L, Cooper S, et al: Synergistic effects of purified recombinant human and murine B cell growth factor-1/interleukin-4 on colony formation in vitro by hematopoietic progenitor cells. J Immunol 141:3852, 1988.

247.
Musashi M, Clark SC, Sudo T, et al: Synergistic interactions between interluekin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood 78:1448, 1991.

248.
DeWolf JTM, Beentijes JAM, Esselink MT, et al: Interleukin-4 suppresses the interleukin-3 dependent erythroid colony formation form normal human bone marrow cells. Br J Haematol 74:246, 1990.

249.
Takatsu K, Tominaga A, Mamaoka T: Antigen induced T cell replacing factor (TRF). I. Functional characterization of TRF-producing helper T cell subset and genetic studies on TRF production. J Immunol 124:2414, 1980.

250.
Swain SL, Dutton RW: Production of a B cell growth-promoting activity, (DL) BCGF, from a cloned T cell line and its assay on the BCL1 B cell tumor. J Exp Med 156:1821, 1982.

251.
Tanabe O, Akira S, Kamiya T, et al: Genomic structure of the murine IL-6 gene. J Immunol 141:3875, 1988.

252.
Sehgal PB, May LT, Tamm I, Vilcek J: Human B2 interferon and B cell differentiation factor BSF-2 are identical. Science 235:731, 1987.

253.
Gauldie J, Richards C, Harnish D, et al: Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251, 1987.

254.
Ikebuchi K, Wong GG, Clark SC, et al: Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84:9035, 1987.

255.
Chiu CP, Moulds C. Coffman RL, et al: Multiple biological activities are expressed by a mouse interleukin-6 cDNA clone isolated from bone marrow stromal cells. Proc Natl Acad Sci USA 85:7009, 1988.

256.
Quesenberry PJ, McGrath HE, Williams ME, et al: Multifactor stimulation of megakaryocytopoiesis: effects of IL-6. Exp Hematol 19:35, 1991.

257.
Ishibashi T, Kimura H, Shikama Y, et al: Inteleukin-6 is a potent throbopoietic factor in vivo in mice. Blood 74:1241, 1989.

258.
Herodin F, Mestries J-C, Janodet D, et al: Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood 80:688, 1992.

259.
Cooper RJ, Gordon MS, Weber J, Hoffman R: The in vivo administration of recombinant human interleukin-6 (IL-6) to patients with advanced malignancies has a profound effect on thrombopoiesis. Exp Hematol 21:1117, 1993.

260.
Hoang T, Haman A, Goncalves O, et al: Interleukin-6 enhances growth factor-dependent proliferation of the blast cells of acute myeloblastic leukemia. Blood 72:823, 1988.

261.
Klein B, Zhang X-G, Jourdan M, et al: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517, 1989.

262.
Yoshizaki K, Matsuda T, Nishimoto N, et al: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360, 1989.

263.
Faltynek CR, Wang S, Miller D, et al: Administration of human recombinant IL-7 to normal and irradiated mice increases the number of lymphocytes and some immature cells of myeloid lineage. J Immunol 149:1276, 1992.

264.
McNiece IK, Langley KE, Zsebo KM: The role of recombinant stem cell factor in early B cell development. J Immunol 146:378, 1991.

265.
Schall TJ, Bacon K, Camp RDR, et al: Human macrophage inflammatory protein-1a (MIP-1a) and MIP 1b chemokines attract distinct populations of lymphocytes. J Exp Med 177:1821, 1993.

266.
Volpe SD, Cerami A: Macrophage inflammatory protein 1 and 2: members of a novel super family of cytokines. FASEB J 3:2565, 1989.

267.
Broxmeyer HE, Benninger L, Hague N, et al: Suppressive effects of the chemokine (macrophage inflammatory protein) family of cytokines on proliferation of normal and leukemia myeloid cell proliferation, in The Negative Regulation of Hematopoiesis: From Fundamental Aspects to Clinical Applications, edited by M Guigon. Inserum Eurotext Libbey, Paris, 1993.

268.
Donahue RE, Yang Y-C, Clark SC: Human P40 T cell growth factor (interleukin-9) supports erythroid colony formation. Blood 75:2271, 1990.

269.
VanSnick J, Goethals A, Renauld JC, et al: Cloning and characterization of a cDNA for a new mouse T cell growth factor (P40). J Exp Med 169:363, 1989.

270.
Yang Y-C, Ricciardi S, Ciarletta A, et al: Expression cloning of a cDNA encoding a novel human hematopoietic growth factor human homologue of murine T cell growth factor P40. Blood 74:1880, 1989.

271.
Hueltner L, Moeller J, Schmitt E, et al: Thiol-sensitive mast cell lines derived from mouse bone marrow respond to a mast cell growth-enhancing activity different from both IL-3 and IL-4. J Immunol 142:3440, 1989.

272.
Suda T, O’Garra A, MacNeil I, et al: Identification of a novel thymocyte growth-promoting factor derived from B cell lymphomas. Cell Immunol 147:528, 1991.

273.
Chen W-F, Zlotnick A: IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 147:528, 1991.

274.
Go NF, Castle BE, Barrett R, et al: Interleukin-10, a novel B cell stimulatory factor: unresponsiveness of x chromosome-linked immunodeficiency B cells. J Exp Med 172:1625, 1990.

275.
Yin T, Schendel P, Yu-Chung Y: Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin-11. J Exp Med 175:211, 1992.

276.
Bruno E, Briddell RA, Cooper RJ, Hoffman R: Effects of recombinant interleukin-11 on human megakaryocyte progenitor cells. Exp Hematol 19:378, 1991.

277.
Musashi M, Clark SC, Sudo T, et al: Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood 78:1448, 1991.

278.
Goldman S, Loebelenz J, McCarthy K, et al: Recombinant human interleukin-11 stimulates megakaryoctyic maturation and increase in peripheral platelet number in vivo. Blood 78:1329, 1991 (abstract).

279.
Du XX, Neben T, Goldman S, Williams DA: Effects of recombinant humaninterleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood 81:27, 1993.

280.
Wolf SF, Temple PA, Kobayashi M, et al: Cloning of cDNA for natural killer cells stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074, 1991.

281.
Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827, 1989.

282.
Gately MK, Desai BB, Wolitzky AG, et al: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874, 1991.

283.
Chan SH, Perussia B, Gupta JW, et al: Induction of interferon g production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173:869, 1991.

284.
Kiniwa M, Gately M, Gubler U, et al: Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4-stimulated human lymphocytes. J Clin Invest 90:262, 1992.

285.
McKenize ANJ, Culpepper JA, de Waal Malefyt R, et al: Interleukin-13, a novel T-cell-derived cytokine that regulates human monocyte and B cell function. Proc Natl Acad Sci USA 90:3735, 1993.

286.
Ambrus JL Jr., Chesky L, Stephany D, McFarland P, Mostowski H, Fauci AS: Functional studies examining the subpopulation of human B lymphocytes responding to high molecular weight B cell growth factor. J Immunol 145:3949, 1990.

287.
Ambrus JL Jr., Pippin J. Joseph A. et al: Identification of a cDNA for a human high-molecular-weight B-cell growth factor [published erratum appears in Proc Natl Acad Sci USA 1996 Jul 23;93(15):8154]. Proc Natl Acad Sci USA 90:6330, 1993.

288.
Ford R, Tamayo A, Martin B, Niu K, Claypool K, Cabanillas F, Ambrus J Jr: Identification of B-cell growth factors (interleukin-14; high molecular weight B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas. Blood 86:283, 1995.

289.
Uckun FM, Fauci AS, Chandan-Langlie M, Myers DE, Ambrus JL: Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia. J Clin Invest 84:1595, 1989.

290.
Bamford RN, Battiata AP, Waldmann TA: IL-15: the role of translational regulation in their expression. J Leuk Biol 59:476, 1996.

291.
Giri J, Anderson DM, Kumaki S, et al: IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2, J Leuk Biol 57:763, 1995.

292.
Kennedy MK, Park LS: Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J Clin Immunol 16:134, 1996.

293.
Tagaya Y, Bamford RN, DeFilippis AP, Waldman TA: IL-15: a pleoriophic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 4:329, 1996.

294.
Kirman I, Vainer B, Nielsen OH: Interleukin-15 and its role in chronic inflammatory diseases. Inflam Res 47:285, 1998.

295.
Center DM, Kornfeld H, Cruikshank WW: Interleukin-16. Int J Biochem Cell Biol 29:1231, 1997.

296.
Center DM, Kornfeld H, Cruikshank WW: Interleukin-16 and its function as a CD4 ligand. Immunol Today 17:476, 1996.

297.
Cruikshank WW, Kronfeld H, Center DM: Signaling and functional properties of interleukin-16. Int Rev Immunol 16:523, 1998.

298.
Amiel C, Darcissac E, Truong MJ, et al: Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J Infect Dis 179:83, 1999.

299.
Mashikian MV, Tarpy RE, Saukkonen JJ, et al: Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol 101:786, 1998.

300.
Antonaci S, Serlenga E, Garofalo AR, et al: Imbalance of T cell immunoregulatory subsets in primary lgA nephropathy. Cytobios 59:95, 1989.

301.
Klimiuk PA, Goronzy JJ, Weyand CM: IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 162:4293, 1999.

302.
Lee S, Kaneko H, Sekigawa I, et al: Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheum 37:1334, 1998.

303.
Laberge S, Ghaffar O, Boguniewicz M, et al: Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol 102:645, 1998.

304.
Spriggs, MK: Interleukin-17 and its receptor. J Clin Immunol 17:366, 1997.

305.
Fossiez F, Banchereau J, Murray R, et al: Interleukin-17. Inter Rev Immunol 16:541, 1998.

306.
Yao Z, Spriggs MK, Derry JM, et al: Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9:794, 1997.

307.
Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162:1246, 1999.

308.
Shin HC, Benbernou N, Fekkar H, et al: Regulation of IL-17, IFN-gamma and IL-10 in human CD8(+) T cells by cyclic AMP-dependent signal transduction pathway. Cytokine 10:841, 1998.

309.
Chabaud M, Durand JM, Buchs N, et al: Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:963, 1999.

310.
Awane M, Andres PG, Li DJ, Reinecker HC: NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 162:5337, 1999.

311.
VanKooten C, Boonstra JG, Paape ME, et al: Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 9:1526, 1998.

312.
Cai XY, Gommoll CP Jr, Justice L, et al: Regulation of granulocyte colony-stimulating factor gene expression by interleukin-17. Immunol Letters 62:51, 1998.

313.
Jovanvic DV, Di Battista JA, Martel-Pelletier J, et al: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:3513, 1998.

314.
Shalom-Barak T, Quach J, Lotz M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 273:27467, 1998.

315.
Teunissen MB, Koomen CW, de Waal Malefyt R, et al: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Derm 111:645, 1998.

316.
Albanesi C, Cavani A, Girolomoni G: IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 162:494, 1999.

317.
Hoshino H, Lotvall J, Skoogh BE, Linden A: Neutrophil recruitment by interleukin-17 into rat airways in vivo. Role of tachykinins. Am J Resp Crit Care Med 159:1423, 1999.

318.
Hoshino H. Lotvall J. Skoogh BE. Linden A. Neutrophil recruitment by interleukin-17 into rat airways in vivo. Role of tachykinins. Am J Resp Crit Care Med 159:1423, 1999.

319.
Schwarzenberger P, La Russa V, Miller A, et al: IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 161:6383, 1998.

320.
Gillespie MT. Horwood NJ: Interleukin-18: perspectives on the newest interleukin. Cytokine Growth Factor Rev 9:109, 1998.

321.
Dinarello CA, Novick D, Puren AJ, et al: Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leuk Biol 63:658, 1998.

322.
Okamura H, Kashiwamura S, Tsutsui H, et al: Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 10:259, 1998.

323.
Brummer E: Human defenses against Cryptococcus neoformans: an update. Mycopathologia 143:12, 1998–99.

324.
Fantuzzi G, Dinarello CA: Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol 19:1, 1999.

325.
Corsini E, Galli CL: Cytokines and irritant contact dermatitis. Toxicol Lett 102-103:277, 1998.

326.
Dinarello CA: Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 856:1, 1998.

327.
Dinarello CA: IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103:11, 1999.

328.
Okamura H, Tsutsui H, Kashiwamura S, et al: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70:281, 1998.

329.
Martin TJ, Romas E, Gillespie MT: Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryotic Gene Expression. 8:107, 1998.

330.
Dinarello CA: Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16:457, 1998.

331.
Rothe H. Kolb H: The APC1 concept of type I diabetes. Autoimmunity 27:179, 1998.

332.
Murphy KM: Lymphocyte differentiation in the periphery. Curr Opin Immunol 10:226, 1998.

333.
Revoltella RP: Natural and therapeutically-induced antibodies to cytokines. Biotherapy. 10:321, 1998.

334.
Fukumoto H, Nishio M, Nishio K, et al: Interferon-gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jap J Cancer Res 88:501, 1997.

335.
Russell ES, Smith LJ, Lawson FA: Implantation of normal blood-forming tissue in radiated genetically anemic hosts. Science 124:1076, 1956.

336.
Russell ES, Bernstein SE: Proof of whole-cell implant in therapy of W-series anemia. Arch Biochem Biophys 125:594, 1968.

337.
Russell ES: Hereditary anemias of the mouse: a review of geneticists. Adv Genet 20:357, 1979.

338.
Mintz B, Russell ES: Gene-induced embryological modifications of primordial germ cells in the mouse. J Exp Zool 134:207, 1957.

339.
Bernstein SE, Russell ES, Keighley G: Two hereditary mouse anemias (S1/S1d and W/Wv) deficient in response to erythropoietin. Ann N Y Acad Sci 149:475, 1968.

340.
Fried W, Camberlin W, Knospe WH, et al: Studies on the defective hematopoietic microenvironment of S1/S1d mice. Br J Haematol 24:643, 1973.

341.
McCulloch EA, Siminovitch L, Till JE, et al: The cellular basis of the genetically determined hemopoietic defect in anemic mice of genotype S1/S1d. Blood 26:399, 1965.

342.
Mayer TC, Green MC: An experimental analysis of the pigment defect caused by mutations at the W and S1 loci in mice. Dev Biol 18:62, 1968.

343.
Mayer TC: A comparison of pigment cell development in albino, stell and dominant-spotting mutant mouse embryos. Dev Biol 23:297, 1970.

344.
Chabot B, Stephenson DA, Chapman VM, et al: The proto-oncogene c-Kit encoding a transmembrane tyrosin kinase receptor maps to the mouse W locus. Nature 335:88, 1988.

345.
Geissler EN, Ryan MA, Housman DE: The dominant-whitespotting (W) locus of the mouse encodes the c-Kit proto-oncogene. Cell 55:185, 1988.

346.
Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, et al: Human protooncogene c-Kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341, 1987.

347.
Tan JC, Nocka K, Ray P, et al: The dominant W42 spotting phenotype results from a missense mutation in the c-Kit receptor kinase. Science 247:209, 1990.

348.
Nocka K, Majumder S, Chabot B, et al: Expression of c-Kit gene products in known cellular targets of W mutations in normal and W mutant mice—evidence for an impaired c-Kit kinase in mutant mice. Genes Dev 3:816, 1989.

349.
Nocka, K, Tan JC, Chiu E, et al: Molecular basis of dominant negative and loss of function mutations at the murine c-Kit receptor. Genes Dev 4:390, 1990.

350.
Reith AD, Rottapel R, Giddens E, et al: W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-Kit receptor. Genes Dev 4:390, 1990.

351.
Majumder S, Brown K, Qiu F-H, Besmer P: c-Kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol 8:4896, 1988.

352.
Nocka K, Buck J, Levi E, Besmer P: Candidate ligand for the c-Kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates most cells and erythroid progenitors. Embo J 9:3287-94, 1990.

353.
Zsebo KM, Wypych J, McNiece IK, et al: Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver conditioned media. Cell 63:195-201, 1990.

354.
Copeland NG, Gilbert DJ, Cho BC, et al: Most cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63:175, 1990.

355.
Wehrle-Haller B, Weston JA: Soluble and cell-bound forms of steel factor activity play distinct roles in melanocyte precursor dispersal and survival on the lateral neural crest migration pathway. Development 121:731, 1995.

356.
McDonald TP: Thrombopoietin: its biology, purification and characterization. Exp Hematol 16:201, 1988.

357.
Hill RJ, Levin J: Regulators of thrombopoiesis: their biochemistry and physiology. Blood Cells 15:141, 1989.

358.
Ebbe S: Forward, in Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology, edited by DJ Kuter, P Hunt, W Sheridan, D Zucker-Franklin, pp V-XI. Human Press, Totowa, NJ, 1997.

359.
Vigon I, Mornon JP, Cocault L, et al: Molecular cloning and characterization of MPL, the human hemolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 89:5640, 1992.

360.
Souyri M, Vigon I, Penciolelli J-F et al: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalization hematopoietic progenitors. Cell 63:1137, 1990.

361.
Wendling F, Varlet P, Charon M, et al: A retrovirus complex inducting an acute myeloproliferative leukemia disorder in mice. Virology 149:242, 1986.

362.
DeSauvage FJ, Hass PE, Spencer SD, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533, 1994.

363.
Lok S, Kaushansky K, Holly RD, et al: Cloning and expression of murine thrombopoietin eDNA and stimulation of platelet production in vivo. Nature 369:565, 1994.

364.
Bartley TD, Bogenberger J, Hunt P, et al: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77:1117, 1994.

365.
Sohma Y, Akahori H, Seki N, et al: Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 353:57, 1994.

366.
Kaushansky K: Thrombopoietin: the primary regulator of platelet production. Blood 86:419, 1995.

367.
Kaushansky K, Lin N, Grossman A, et al: Thrombopoietin expands erythroid, granulocyte-macrophage and megakaryocyte progenitor cells in normal and myelosuppressed mice. Exp Hematol 23:265, 1996.

368.
Forese AM, Hunt P, Grab LB, Mac Vittre: Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multi-lineage hematopoietic reconstitution in non-human primates after irradiation induced marrow aplasia. J Clin Invest 97:2145, 1996.

369.
Ku H, Yonemura Y, Kaushonsky K, Ogawa M: Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early-acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 87:4544, 1991.

370.
Petzor AL, Sandstra PW, Piret JM, Eaves CJ: Differential cytokine effects on primitive (CD34+ CD38-) human hematopoietic cells: novel responses to Flt-3 ligand and thrombopoietin. J Exp Med 183:2551, 1996.

371.
Solar GP, Kerr WG, Zeigler FC, et al: Role of c-Mpl in early hematopoiesis. Blood 92:4, 1998.

372.
Kimura S, Roberts AW, Metcalf D, Alexander WS: Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 95:1195, 1998.

373.
Jacobsen SEM, Ruscetti FW, Dubois CM, et al: Transforming growth factor beta transmodulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood 77:1706, 1991.

374.
Cosman D, Lyman SD, Idzerda RL, et al: A new cytokine receptor superfamily. Trends Biochem Sci 15:265, 1990.

375.
D’Andrea AD, Fasman GD, Lodish HF: A new hematopoietic growth factor receptors superfamily: structural features and implications for signal transduction. Curr Opin Cell Biol 2:648, 1990.

376.
Bazan JF: Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 87:6934, 1990.

377.
Miyajima A, Hayashida K, Itoh N, et al: Molecular structure of the receptors for GM-CSF, IL-3 and IL-5, in Molecular Biology of Hematopoiesis, edited by NG Abraham et al vol 2, p 119. Intercept, Ltd, 1992.

378.
Welham MJ, Dechert U, Leslie KB, et al: Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 and Grb2 and phosphatidylinsoitol 3′-kinase. J Biol Chem 269:23764, 1994.

379.
Okuda K, Smith L, Griffin JD, et al: Signaling functions of the tyrosine residues in the Bc chain of the glanulocyte-macrophage colony-stimulating factor receptor. Blood 90:4759, 1997.

380.
Welham MJ, Bone H, Levings M, et al: Insulin receptor substrate-2 is the major 170-kDa protein phoespharylaed on tyrosine in response to cytokines in murine lymphohematopoietic. J Biol Chem 272:1377, 1997.

381.
Odai H, Sasaki K, Iwamatsu A, et al: The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J Biol Chem 270:10800, 1995.

382.
Hanazono Y, Odai H, Sasaki K, et al: Proto-oncogene products Vav and c-Cb1 are involved in the signal transduction through Grb2/Ash in hematopoietic cells. Acta Hematol 95:236, 1996.

383.
Inhorn RC, Carlesso N, Durstin M, et al: Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci USA 92:8665, 1995.

384.
Sato N, Sakamaki K, Teroda N, et al: Signal transduction by the high affinity GM-CSF receptor: two distinct cytoplasmic regions of the common B subunit responsible for different signaling. Embo J 12:4181, 1993.

385.
Matsuguchi T, Inhorn RC, Carlesso N, et al: Tyrosine phosphorylation of p95 Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210 BCR/ABL, Embo J 14:257, 1995.

386.
Itoh T, Liu R, Yokota T, et al: Definition of the role of tyrosine residues of the common beta subunit regulating multiple signaling pathways of granulocyte macrophage colony-stimulating factor receptor. Mol Cell Biol 18:742, 1998.

387.
Odai H, Sasaki K, Iwamatsu A, et al: Purification and molecular cloning of SH2 and SH3-containing inosital polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl. Blood 89:2745, 1997.

388.
Mui A-lF, Wakao H., O’Farrell A-M, et al: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. Embo J 14:1166, 1995.

389.
Quelle FW, Sato N, Wilthuhn BA, et al: JAK2 associates with the Bc chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane proximal region. Mol Cell Biol 14:4335, 1994.

390.
Chaturvedi P, Reddy MV, Reddy EP: Src kinases and not JAK’s activate STATS during IL-3 induced myeloid cell proliferation. Oncogene 16:1749, 1998.

391.
Guthridge MA, Stomski FC, Thomas D, et al: Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells 16:301, 1998.

392.
Weissman SM, Perkins AS: Stem cell transcription, in Stem Cell Biology and Gene Therapy, edited by PJ Quesenberry, GS Stein, B Forget, S Weissman, pp 81–131. Wiley-Liss, New York.

393.
Wadman IA, Osacla H, Grutz GG, et al: The LIM – only protein Lmo2 is a bridging molecule resembling an erythroid, DNA-binding complex which includes the TALI, E47, GAT-1 and Ldbl/NLI proteins. Embo J 16:3145, 1997.

394.
Bjornson CRR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283:534, 1999.

395.
Jackson KA, Ticjugn MI, Goudell MA: Hematopoietic stem cells in adult skeletal muscle. Presented at Inter Soc Exp Hematol meeting, Monte Carlo, July 12, 1999.

396.
Bruder SP, Kurth AA, Shea M, Hayes WC, Jaiswal N, Kadiyala S: Bone regeneration by implantation of purified culture-expanded human mesenchymal stem cells. J Orthop Res 16:155, 1998.

397.
Petersen BE, Bowen WC, Patrene KD, et al: Bone marrow as a potential source of hepatic oval cells. Science 284:1168, 1999.

398.
Moore MA, Metcalf D: Ontogenesis of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo. Br J Haematol 18:279, 1970.

399.
Dieterlen-Lievre F: On the origin of haemopoietic stem cells in the avian embryo: an experimental approach. J Embryol Exp Morphol 33:607, 1975.

400.
Cumaro A, Furlonger C, Paige CJ: Differentiation and characterization of B-cell precursors detected in the yolk sac and embryo body of embryos beginning at the 10- to 12-somite stage. Proc Natl Acad Sci USA 90:6429, 1993.

401.
Cumaro A, Dieter-lenLievre F, Godin I: Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86:907, 1996.

402.
Godin I, Garcia-Porrono JA, Coutin HO, et al: Para-aortic splanchnopleura from early mouse embryos contains B1a cell progenitors. Nature 364:67, 1993.

403.
Meduinsky A, Dzierzak E: Definitive hematopoiesis is autonomously initiated by the A6M region. Cell 86:897, 1996.

404.
Meduinsky AL, Samoylina NL, Muller AM, Dzierzak EA: An early pre-liver intra-embryonic source of CFU-s in the developing mouse. Nature 364:64 1993.

405.
Muller AM, Meduinsky A, Strouboulis J, et al: Development of hematopoietic stem cells activity in the mouse embryo. Immunity 1:291, 1994.

406.
Choi H, Kennedy M, Kazarov A, et al: A common precursor for hematopoietic and endothelial cells. Development 125:725, 1998.

407.
Liao EC, Zon LI: Conservation of themes in vertebrate blood development, in Cell Lineage and Fate Determination, edited by SA Moody, pp 569–578. Academic Press, New York, 1999.

408.
Quesenberry PJ: Unpublished observation, 1999.

409.
Sprangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoietic stem cells. Science 241:58, 1988.

410.
Ogawa M, Matsuzaki Y, Nichikawa S, et al: Expression and function of c-kit in hematopoietic progenitor cells. J Exp Med 174:67, 1991.

411.
Zeigler FC, Bennett BD, Jordan CT, et al: Cellular and molecular characterization of the role of the FLK-2/FLT-3 receptor tyrosine kinase in heamatopoietic stem cells. Blood 84:2422, 1994.

412.
Krause DS, Fackler MJ, Civin CL, May WS: CD34: Structure, biology and clinical utility. Blood 87:1, 1996.

413.
Pettergell R, Moore MAS: Hematopoietic stem cells: proliferation, purification and clinical application, in Stem Cell Biology and Gene Therapy, edited by PJ Quesenberry, GS Stein, B Forget, S Weissman, pp 133–159. Wiley-Liss, New York.

414.
Watt SM, Visser JW: Recent advances in the growth and isolation of primitive haemopoietic progenitor cells. Cell Prolif 25:263, 1992.

415.
Miraglia S, Godrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. Blood 90:5013, 1997.

416.
Craig W, Kay R, Cutler RL, Landsdorp PM: Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 177:1331, 1993.

417.
Landsdorp PM, Dragowska W, Mayan H: Ontogene-related changes in proliferative potential of human hematopoietic cells. J Exp Med 178:787, 1993.

418.
Osawa M, Hanada K, Homeda H, Nakauch H: Long-term lympho hematopoietic reconstitution by a single D34-low/negative hematopoietic stem cell. Science 273:242, 1996.

419.
Zanjani ED, Almeida-Porada G, Livingston AG, Flae AW, Ogowa M: Human bone marrow CD34- cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. Exp Hematol 26:353, 1998.

420.
Sato T, Laver JH, Ogawa M: Reversible expression of CD34 by murine hematopoietic stem cells. Blood 94:2548, 1999.

421.
Chaudry PM, Roninson IB: Expression and activity of P-glycoprotein: a multidrug efflux pump in human hematopoietic stem cells. Cell 66:85, 1991.

422.
Bertoncello I, Hodgson GS, Bradley TR: Multiparameter analysis of transplantable hemopoietic stem cells. The separation and enrichment of stem cells homing to marrow and spleen on the basis or rhodamine-124 fluorescence. Exp Hematol 13:99, 1985.

423.
Mulder AH, Visser JWM: Separation and functional analysis of bone marrow cells separated by rhodamine-123 fluorescence. Exp Hematol 15:99, 1987.

424.
Ploemacher RE, Brons NHC: Cells with marrow and spleen repopulating ability and forming spleen colonies on days 16, 12 and 8 are sequentially ordered on the basis of increasing rhodamine-123 retention. J Cell Physiol 136:531, 1988.

425.
Sitnicka E, Bartelmez SH, Wolf NS: Separation of distinct subpopulations of primitive hematopoietic stem cells: in vivo and in-vitro characteristics. Exp Hematol 21:378, 1993.

426.
Bradford GB, Williams B, Rossi R, Bertoncello I: Quiescence, cycling and turnovers in the primitive hemapoietic stem cell compartment. Exp Hematol 25:445, 1997.

427.
Pang L, Reddy PV, Quesenberry PJ: Are bone marrow stem cells quiescent? Exp Hematol 27(suppl 1):106, 1999.

428.
Reddy GPV, Tiarks CY, Pang L, Quesenberry PJ: Synchronization and cell cycle analysis of pluripotent hematopoietic progenitor stem cells. Blood 90:2293, 1997.

429.
Nilsson SK, Dooner MS, Quesenberry PJ: Synchronized cell-cycle induction of engrafting long-term repopulating stem cells. Blood 90:4646, 1997.

430.
Frimberger AE, McAuliffe CI, Tuft RA, Quesenberry PJ: Studies of hematopoietic stem cell movement and membrane protrusions. Submitted International Society for Experimental Hematology, 1999.

431.
Frimberger AE, Stering AI, Tuft RA, et al: An in vitro model of hematopoietic stem cell homing. Blood 92:585a, 1998.

432.
Bunting KD, Galipeau J, Topham D, et al: Effects of retro-viral-mediated MDRI expression on hematopoietic stem cell self-renewal and differentiation in culture, in Hematopoietic Stem Cells Biology and Transplantation, edited by D Orlic, TA Bock, L Kanz, pp 125–141. New York Academy of Science, New York, 1999.

433.
Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ: Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol 23:461, 1995.

434.
Peters SO, Kittler ELW, Ramshaw HS, Quesenberry PJ: Ex vivo expansion of murine marrow cells with interleukin-3, interleukin-6, interleukin-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 87:30, 1996.

435.
Hababian HK, Peters SO, Hsieh CC, et al: The fluctuating phenotype of the lympho-hematopoietic stem cell with cell cycle transit. J Exp Med 188:393, 1998.

436.
Cooper CL, Brady G, Bilia F, et al: Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system. Blood 89:3135, 1997.

437.
Shakoori R, van Wijnen AJ, Cooper C, et al: Cytokine-induciton of proliferation and expression of CDC2 and cyclin A in FDC- P1 myeloid hematopoietic progenitor cells: regulation of ubiquitous and cell cycle dependent histone gene transcription factors. J Cell Biochem 58:1, 1995.

438.
Pearson-White S, Deacon D, Crittenden R, et al: The ski/sno proto-oncogene family in hematopoietic development. Blood 86:2146, 1995.

439.
Becker PS, Nilsson SK, Zhifang L, et al: Adhesion receptor expression by hematopoietic cell lines and murine progenitors: modulation by cytokines and cell cycle status. Exp Hematol 27:533, 1999.

440.
Carlos TM, Harlan JM: Leukocyte-endothelial adhesion molecules. Blood 84:2068, 1994.

441.
Long MW: Blood cell cytoadhesion molecules. Exp Hematol 20: 288, 1992.

442.
Giancotti FG, Comoglio PM, Tarone G: Fibronectin plasma membrane interaction in the adhesion of hemopoietic cells. J Cell Biol 103:429, 1986.

443.
Tsai S, Patel V, Beaumont E, Lodish HF: Differential binding of erythroid and myeloid progenitors to fibroblasts and fibronectin. Blood 69:1587, 1987.

444.
Koenigsmann M, Griffin JD, DiCarlo J, Cannistra SA: Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood 79:657, 1992.

445.
Williams DA, Rios M, Stephens C, Patel VP: Fibronectin and VLA-4 in hematopoietic stem cell-microenvironment interactions. Nature (London) 352:438, 1991.

446.
Verfaillie CM, Mcarthy JB, McGlave PB: Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 174:693, 1991.

447.
Papayannopoulou T, Nakamoto B: Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 90:9374, 1993.

448.
Papayannopoulou T, Craddock C, Nakamoto B, et al: The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 92:9647, 1995.

449.
Papayannopoulou T, Priestley GV, Nakamoto B: Anti-VLA4/CAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 91:2231, 1998.

450.
Lewinsohn DM, Nagler A, Ginzton N, et al: Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood 75:589, 1990.

451.
Yong KL, Watts M, Thomas NS, et al: Transmigration of CD34+ cells across specialized and non-specialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood 91:1196, 1998.

452.
Aizawa S, Tavassoli M: In vitro homing of hematopoietic stem cells is mediated by a recognition system with galactosyl and mannosyl specificities. Proc Natl Acad Sci USA 84:4485, 1987.

453.
Long MW, Briddell R, Walter AW, et al: Human hematopoietic stem cell adherence to cytokines and matrix molecules. J Clin Invest 90: 251, 1992.

454.
Bruno E, Luikart SD, Long MW, Hoffman R: Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines. Exp Hematol 23:1212, 1995.

455.
Frenette PS, Subbarao S, Mazo IB, et al: Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci 95:14423, 1998.

456.
Wolf NS, Trentin JJ: Hemopoietic colony studies. V. Effect of hemopoietic organ stroma on differentiation of pluripotent stem cells. J Exp Med 127:205, 1968.

457.
Curry JL, Trentin JJ, Wolf N: Hemopoietic spleen colony studies. II. Erythropoiesis. J Exp Med 125:703, 1967.

458.
Bernstein SE: Tissue transplantation as an analytic and therapeutic tool in hereditary anemias. Am J Surg 119:448, 1970.

459.
Bessis M, Mize C, Prenant M: Erythropoiesis: comparison of in vivo and in vitro amplification. Blood Cells 4:155, 1978.

460.
Lichtman MA: The ultrastructure of the hemopoietic environment of the marrow: a review. Exp Hematology 9:391, 1981.

461.
Quesenberry PJ: Stromal cells in long-term bone marrow cultures, in Handbook of the Hemopoietic Microenvironment, edited by M Tavassoli, pp 253–285. Humana Press, New Jersey, 1989.

462.
Quesenberry PJ: Stroma-dependent hematolymphopoietic stem cells, in Current Topics in Microbiology and Immunology, edited by C Muller-Sieburg, vol 177, Hematopoietic Stem Cells, pp 151–166. Springer-Verlag, Berlin-Heidelberg, 1992.

463.
Levitt L, Quesenberry PJ: The effect of lithium on murine hematopoiesis in a liquid culture system. N Engl J Med 302:713, 1980.

464.
Quesenberry PJ, Coppola MA, Gualtieri RJ, et al: Lithium stimulation of murine hematopoiesis in a liquid culture system: an effect mediated by radioresistant stromal cells. Blood 63:121, 1984.

465.
Song ZX, Quesenberry PJ: Radioresistant murine marrow stromal cells: a morphologic and functional characterization. Exp Hematol 12:523, 1984.

466.
Doukas M, Niskanen E, Quesenberry PJ: The effect of lithium on stem cell and stromal cell proliferation in vitro. Exp Hematol 14:215, 1986.

467.
Gualtieri RJ, Shadduck RF, Baker DG, Quesenberry PJ: Hematopoietic regulatory factors produced in long-term bone marrow cultures and the effect of in vitro irradiation. Blood 64:516, 1984.

468.
Song ZX, Shadduck RK, Innes DJ Jr, et al: Hematopoietic factor production by a cell line (TC-1) derived from adherent murine marrow cells. Blood 66:273, 1985.

469.
Quesenberry PJ, Song Z, McGrath HE, et al: Multilineage synergistic activity produced by a murine adherent marrow cell line. Blood 69:827, 1987.

470.
Alberico T, Ihle JN, McGrath HE, et al: Stromal growth factor production in irradiated lectin exposed long-term murine bone marrow cultures. Blood 69:1120, 1987.

471.
McGrath HE, Liang C, Alberico T, Quesenberry PJ: The effect of lithium on growth factor production in long-term bone marrow cultures. Blood 70:1136, 1987.

472.
Nilsson S, Dooner M, Tiarks C, et al: Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 89:4013, 1997.

473.
Fibbe WE, Pruijt JFM, Welders GA, et al: Biology of IL-8 induced stem cell mobilization. Ann N Y Acad Sci 872:71, 1999.

474.
Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cell mobilized by filarastim (G-CSF) on platelet recovery after high doses of chemotheraphy. Lancet 339:640, 1992.

475.
Gianni AM, Siena S, Bregni M., et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for auto transplantation. Lancet 21:580, 1989.

476.
Papayannopoulou T: Hematopoietic stem/progenitor cell mobilization a continuing quest for etcolegic mechanisms, in Hematopoietic Stem Cells—Biology and Transplantation, edited by D Orlic, TA Bock, Kanz L, pp 187–197. New York Academy of Sciences, New York, 1999.

477.
Sheridan W: Cytokine-only approaches to mobilization of progentior cells, in Cell Therapy, edited by G Morstyn, W Sheridan, pp 146–198. Cambridge University, New York, 1996.

478.
Gately MK, Gubler E, Brunde MJ, et al: Interleukin 12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1:187, 1994.

479.
Korbling M: In vivo expansion of the circulating stem cell pool, in Characteristics and Potentials of Blood Stem Cells, edited by TM Fleidner, D Hoelzer D, pp 131–138. Univ. Alpha Med. Press, 1998.

480.
Mauch P, Lamont C, Neben TY, et al: Hematopoietic stem cells in the blood after stem cell factor and interleukin-11 administration: evidence for different mechanisms of mobilization. Blood 86:4673, 1995.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

6 comments on “CHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINES

  1. Thank you very much for your ideas to post comments. The content was really very interesting. I am really thankful to you for providing this unique information. Please keep sharing more and more information….

  2. … [Trackback]…

    […] Read More: medtextfree.wordpress.com/2011/12/26/chapter-14-hematopoietic-stem-cells-progenitor-cells-and-cytokines/ […]…

  3. I was recommended this website via my cousin. I am not certain whether or not this publish is written by him as nobody else recognise such precise approximately my problem. You are incredible! Thank you!

  4. […] 16 Easy Sources of FiberQuestions And Answers On Muscle Building Programs For Menvampires5 Best Carbohydrate Sources For A Flat StomachStructural Aspects Of Protein SynthesisQuick Muscle Building Tips – 4 Tips To Help Quickly Build Muscle MassA Raw Food Diet: Is it Healthier?CHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINES […]

  5. […] approach to treating Type 1 DiabetesDiabetes TreatmentStem Cells May Ease Some Types of BlindnessCHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINESvar base_url_sociable = […]

  6. […] #split {}#single {}#splitalign {margin-left: auto; margin-right: auto;}#singlealign {margin-left: auto; margin-right: auto;}#splittitlebox {text-align: center;}#singletitlebox {text-align: center;}.linkboxtext {line-height: 1.4em;}.linkboxcontainer {padding: 7px 7px 7px 7px;background-color:#eeeeee;border-color:#000000;border-width:0px; border-style:solid;}.linkboxdisplay {padding: 7px 7px 7px 7px;}.linkboxdisplay td {text-align: center;}.linkboxdisplay a:link {text-decoration: none;}.linkboxdisplay a:hover {text-decoration: underline;} function opensingledropdown() { document.getElementById('singletablelinks').style.display = ''; document.getElementById('singlemouse').style.display = 'none'; } function closesingledropdown() { document.getElementById('singletablelinks').style.display = 'none'; document.getElementById('singlemouse').style.display = ''; } Simplifying Practical Eleminate Acne PlansCHAPTER 14 HEMATOPOIETIC STEM CELLS, PROGENITOR CELLS, AND CYTOKINES […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: